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Abstract 
IspG, farnesyl diphosphate synthase (FPPS) and geranylgeranyl diphosphate synthase 
(GGPPS) are enzymes involved in isoprenoid biosynthesis. Most bacterial IspGs contain two 
domains: a TIM barrel (A) and a 4Fe4S domain (B), but in plants and malaria parasites there is a 
large insert domain (A*) whose structure and function are unknown. We show bacterial IspGs 
function in solution as (AB)2 dimers and mutations in either both A or both B domains block 
activity. Chimeras harboring an A-mutation in one chain and a B-mutation in the other have 50% 
of the activity seen in wild-type protein, since there is still one catalytically active AB domain. 
However, a plant IspG functions as an AA*B monomer and we propose using computational 
modeling and electron microscopy that the A* insert domain has a TIM barrel structure that 
interacts with the A domain. This structural arrangement enables the A and B domains to interact 
in a “cup and ball” manner during catalysis, just as in the bacterial systems. EPR/HYSCORE 
spectra of reaction intermediate, product and inhibitor ligands bound to both two and three 
domain proteins are identical, indicating the same local electronic structure, and computational 
docking indicates these ligands bridge both A and B domains. Overall, the results are of broad 
general interest since they indicate the insert domain in three-domain IspGs is a second TIM 
barrel that plays a structural role and that the pattern of inhibition of both two and three domain 
proteins are the same, results that can be expected to be of use in drug design.  
We have found geranylgeranyl diphosphate synthase (GGPPS), a dual-functional enzyme 
that produces farnesyl diphosphate and geranylgeranyl diphosphate appears to be a good target. 
Lipophilic bisphosphonates as well as a new class of inhibitor, benzoic acids, have good 
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inhibition (Ki~1µM) against Plasmodium vivax GGPPS. Benzoic acid analogs have been 
synthesized and tested against PvGGPPS. Crystal structures of several lipophilic 
bisphosphonates as well as benzoic acid derivatives bound to PvGGPPS have been solved. The 
lipophilic bisphosphonate (BPH-703) binds to the FPP site, but all benzoic acids bind to the IPP 
site. 
Human FPPS has been proved to be a validated drug target for osteoporosis-related diseases 
and cancers. We found that the BPH-703 and its analogs have an effect on chain length 
dependence against HsFPPS and PvGGPPS enzymes as well as cells (Plasmodium parasites), in 
vitro. Activation of γδ T cell experiment shows similar effects on chain length variation. Crystal 
structure of HsFPPS bound to BPH-1260, a C4 version of zoledronate with a hydroxyl group on 
the bisphosphonate group explains the intrinsic properties of chain length dependence of 
BPH-703 derivatives. Making potent and selective inhibitors against these three enzymes are 
important as anti-cancer and anti-infective agents. 
iv 
 
Acknowledgements 
It has been five years since the first day I shook Prof. Oldfield’s hands and joined his group. 
Every seconds and minutes were indispensable and valuable to me. I remembered the time when 
we discussed and argued with the results and finally we had a consensus to put all the data 
together as several papers. I enjoyed the moments talking to Prof. Oldfield. Most importantly, his 
suggestions were often extremely useful. His organizational skills were really impressive. He 
taught me how to transform mere ideas into real-life concepts and put them into more feasible 
routes not only through the process of conducting experiments or writing papers, but also by 
means of preparing grant proposals for funding agencies.  
I must thank all the members of the Oldfield’s group whom I dealt with in the past and the 
present. In the first few years, Dr. Fu-Yang Lin was a great partner to me until he received his 
doctorate. . We discussed lots of results in CrtM or SQS projects as well as figured out ways of 
improving the quality of our data. His suggestions, of scientific nature or otherwise, were always 
useful to me. Dr. Rong Cao and I had a lot of valuable conversations across biological assays to 
the field of protein crystallography. He assisted me to expand my knowledge of protein 
crystallography at a whole new level. Dr. Yonghui Zhang is a very knowledgeable professional. 
Our close collaboration in PvGGPPS and HsFPPS projects resulted in development of potent 
inhibitors in against malaria and cancers. This precious relationship will be carried on 
continuously in future. I must thank Dr. Weixue Wang for his precious instructions and 
experiences in iron-sulfur proteins. He instructed me how to use EPR facilities and obtained 
many important spectra. Dr. Ke Wang and Dr. Kai Li are two experienced and dedicated 
v 
 
postdocs who helped me overcome many obstacles. Initially, I didn’t realize synthesizing 
epoxide HMBPP is a time-consuming work until Ke explained to me, but he synthesized it in 
bulk amount for me to test. His contributions to the iron-sulfur protein projects are greatly 
appreciated. Kai has been a really good labmate since he joined our group. The new projects we 
are working on are fascinating and I believe we will have our rewards in a near timeline.  
Francisco, I couldn't forget how much effort you have put into this GcpE project. I cannot 
imagine getting those jobs done without your contribution in electron microscopy and others. I 
remembered the last couple months you and I traveled back and forth between our building, 
MRL and Beckman Institute. The only purpose for us was get used to the instruments, and of 
course, to obtain some exciting images. The project made a huge leap due to your expertise on 
EM and related experiences. Thank you, Francisco! 
Wei Zhu, Xinxin Feng and Janish Desai have been helped a lot on the biological assays and 
several sample preparations. I can’t do without you folks if any pieces of information missed in 
the projects. Jikun Li contributed a lot on synthesizing the critical substrate MEcPP for GcpE 
project, and of course, many hours while we were discussing our research. I have to thank you all 
for your important contribution. Yang Wang, our time spent in the lab really help me to focus on 
the research. I must thank many of undergraduate students whom I have guided and taught. Your 
contributions in many of my projects have helped tremendously. I have to especially point out 
Kevin Houlihan, a former undergraduate in Biochemistry. It was my pleasure to work with you. 
Your true contributions in all three projects, GcpE, PvGGPPS and HsFPPS made them possible. 
I couldn't finish the projects without your inputs. Your dedications in conducting experiments 
vi 
 
and quick-learning skills made working with you a great delight.  
Last and the most important part: I have to say a big THANK YOU to my dear parents, 
Jian-Lu Liu and Ling-Hui Lin as well as my brother, Wei-Liang Liu. They give me a lot of 
strength. They have educated me, cultured me and guided me to the right path. In addition, they 
always have put big smiles on their faces and showed the positive attitude. They always told me 
to be myself and promoted me to pursuit my career path. It is their encouragement to give me 
strength during my five years of PhD life. Now, my dream finally comes true. Thank you. 
I need to show my deepest gratitude to my wife – Ya-Lin Pan. I am really lucky having her 
in my life and make her a true companion. 
In addition, I must thank all of other current or past colleagues, collaborators, friends and 
those I haven’t had a chance to mention in my dissertation. I am glad we can work together and 
ignited lots of shining sparkles. 
  
vii 
 
Table of Contents 
 
Abbreviations .................................................................................................................................. x	  
Chapter 1: Introduction ................................................................................................................... 1	  
1.1 Mevalonate and Non-mevalonate Pathway ........................................................................... 1	  
1.2 (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate Synthase (GcpE, IspG) and 
(E)-4-hydroxy-3-methylbut-2-enyl-diphosphate Reductase (LytB, IspH) as Drug Targets ....... 4	  
1.3 Farnesyl Diphosphate Synthase and Geranylgeranyl Diphosphate Synthase as Drug  
Targets ......................................................................................................................................... 8	  
1.4 Research Strategies ............................................................................................................. 12	  
1.4.1 Studying the Mechanism of Action and Inhibition of Bacterial and Plant GcpEs ....... 12	  
1.4.2 Development of Potent Homoallyic Site Inhibitors Against PvGGPPS ...................... 14	  
1.4.3 Chain Length Variation of Lipophilic Bisphosphonate Against HsFPPS .................... 17	  
1.5 Figures ................................................................................................................................. 18	  
1.6 References ........................................................................................................................... 27	  
Chapter 2: Structure, Function and Inhibition of the Two- and Three-domain 4Fe-4S IspG 
Proteins ......................................................................................................................................... 39	  
2.1 Acknowledgements and Other Contributions ..................................................................... 39	  
2.2 Introduction ......................................................................................................................... 39	  
2.3 Results and Discussion ........................................................................................................ 42	  
2.3.1 IspG Quaternary Structures .......................................................................................... 43	  
2.3.2 Protein-Protein and Protein-Ligand Interactions .......................................................... 46	  
2.3.3 Spectroscopy and Quantum Chemistry ........................................................................ 47	  
2.3.4 Inhibitor Binding .......................................................................................................... 49	  
2.3.5 The Insert Domain (A*) is a TIM Barrel ...................................................................... 50	  
2.4 Conclusions ......................................................................................................................... 53	  
2.5 Methods ............................................................................................................................... 53	  
2.6 Supplementary methods ...................................................................................................... 54	  
2.6.1 Homology Modeling ..................................................................................................... 54	  
viii 
 
2.6.2 Computational Docking ................................................................................................ 55	  
2.6.3 Quantum Chemical Calculations .................................................................................. 56	  
2.6.4 Mutagenesis and Chimera Formation ........................................................................... 57	  
2.6.5 Protein Expression, Purification, Reconstitution and Activity Determination ............. 58	  
2.6.6 Size Exclusion Chromatography .................................................................................. 63	  
2.6.7 Cross-linking Experiment ............................................................................................. 63	  
2.6.8 Enzyme Inhibition ........................................................................................................ 63	  
2.6.9 Transmission Electron Microscopy .............................................................................. 64	  
2.6.10 SI References .............................................................................................................. 66	  
2.7 Figures and Tables .............................................................................................................. 71	  
2.8 References ........................................................................................................................... 90	  
Chapter 3: Benzoic Acids as Anti-malarial Drug Agents: A Crystallographic Investigation ...... 95	  
3.1 Acknowledgements and Other Contributions ..................................................................... 95	  
3.2 Introduction ......................................................................................................................... 95	  
3.3 Results and Discussion ........................................................................................................ 97	  
3.4 Conclusions ....................................................................................................................... 103	  
3.5 Materials and Methods ...................................................................................................... 103	  
3.5.1 Expression and Purification of PvGGPPS .................................................................. 103	  
3.5.2 Inhibition Assay of PvGGPPS .................................................................................... 104	  
3.5.3 Crystallization of PvGGPPS ....................................................................................... 104	  
3.5.4 Pharmacophore Search ............................................................................................... 105	  
3.5.5 Quantitative Structure–Activity Relationship (QSAR) Investigation ........................ 105	  
3.6 Figures and Tables ............................................................................................................ 107	  
3.7 References ......................................................................................................................... 119	  
Chapter 4: Chemo-Immunotherapeutic Anti-Malarials Targeting Isoprenoid Biosynthesis ...... 124	  
4.1 Acknowledgements and Other Contributions ................................................................... 124	  
4.2 Introduction ....................................................................................................................... 124	  
4.3 Results and Discussions .................................................................................................... 126	  
ix 
 
4.4 Conclusions ....................................................................................................................... 128	  
4.5 Materials and Methods ...................................................................................................... 129	  
4.5.1 Human FPPS Expression and Inhibition .................................................................... 129	  
4.5.2 P. vivax GGPPS Expression and Inhibition ................................................................ 130	  
4.5.3 γδ T cell Activation Assays ........................................................................................ 131	  
4.5.4 Crystallization, Data Collection and Refinement of the HsFPPS•5 Complex ........... 132	  
4.5.5 P. falciparum Growth Inhibition Assays .................................................................... 132	  
4.5.6 Computational Aspects ............................................................................................... 133	  
4.6 Figures and Tables ............................................................................................................ 135	  
4.7 References ......................................................................................................................... 141	  
 
 
x 
 
Abbreviations 
IPP, isopentyl diphosphate; DMAPP, dimethylallyl diphosphate; MEP, 2C-methyl-D-ery-thritol 
4-phosphate; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; DOXP, 
1-deoxy-D-xylulose-5-phosphate; DOXP, 1-deoxy-D-xylulose-5-phosphate; CDP-ME, 
4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol; CDP-MEP, 2-phospho-4-(cytidine 
5'-diphospho)-2-C-methyl-D-erythritol; MEcPP, 2-C-methyl-D-erythritol-2,4-cyclodiphosphate; 
HMBPP, hydroxymethylbutenyl; GcpE/IspG, (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate 
synthase; LytB/IspH, (E)-4-hydroxy-3-methylbut-2-enyl-diphosphate reductase; CW-EPR, 
continuouswave electron paramagnetic resonance; ENDOR, electron nuclear double resonance; 
HYSCORE, hyperfine sub-level correlation; PFT, farnesyl transferase; FPP, farnesyl 
diphosphate; GGPP, geranylgeranyl diphosphate; FPPS, farnesyl diphosphate synthase; GGPPS, 
geranylgeranyl diphosphate synthase; ZOL, zoledronate; CrtM, dehydrosqualene synthase; EM, 
electron microscopy 
1 
 
Chapter 1: Introduction 
1.1	  Mevalonate	  and	  Non-­‐mevalonate	  Pathway	  
Two important biosynthetic pathways, mevalonate and non-mevalonate pathways, govern 
the essential precursors across all three domains of life (bacteria, eukaryotes and archaea). The 
five carbons isoprenoid building blocks isopentyl diphosphate (1, IPP) and the dimethylallyl 
diphosphate (2, DMAPP) are made by these two distinct biosynthetic pathways: a classical 
mevalonate pathway or an alternative 2C-methyl-D-ery-thritol 4-phosphate (MEP) pathway 
(Figure 1.1) [1-5]. Both pathways are essential for survival of animals, microbes, bacteria and 
many other species [6-8].  
A classical mevalonate pathway occurs in a series of enzymatic reactions (Figure 1.1) [8]. 
The starting material acetyl-CoA is utilized by an enzyme called acetyl-CoA acetyltransferase. 
Acetyl-CoA acetyltransferase transports one acetyl group to acetyl-CoA and then makes 
acetoacetyl-CoA. Acetoacetyl-CoA is subsequently catalyzed by 
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) synthase to form HMG-CoA. HMG-CoA is then 
catalyzed by the following enzyme HMG-CoA reductase to form mevalonate, which is the key 
molecule in this pathway. Mevalonate is then phosphorylated to become 
mevalonate-5-phosphate (phosphomevalonate or mevalonate-P) by mevalonate kinase. 
Mevalonate-P is further phosphorylated by phosphomevalonate kinase to from 
diphosphomevalonate (mevalonate-PP). Mevalonate-PP is then converted into the penultimate 
molecule IPP by enzyme called mevalonate-PP decarboxylase. IPP has the ability to form an 
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isomer DMAPP by another enzyme named IPP/DMAPP isomerase. IPP and DMAPP will then 
be used as precursors in the downstream biosynthetic or signal transduction pathways. 
Some of the enzymes in the mevalonate pathway have been proved to be validated drug 
targets [9-12]. Since the first discovery of statin as a natural product in 1971 [13], there were 
many statins being made so far [14]. For example, the well-known drug atorvastatin (3, branded 
name Lipitor), is the top selling blockbuster drug manufactured by Pfizer in contribution for tens 
of billion dollars every year (Scheme 1.1). Other statin drugs, e.g. lovastatin (4, branded name 
Mevacor), pitavastatin (5, branded name Livalo, Pitava), pravastatin (6, branded name Pravachol, 
Selektine or Lipostat), rosuvastatin (7, branded name Crestor) and simvastatin (8, branded name 
Zocor or Lipex), are all statin-related drugs used clinically. The ultimate enzyme inhibited by 
statins is HMG-CoA reductase (Figure 1.1). Inhibiting HMG-CoA reductase, statins play a role 
as cholesterol-lowering agents [13]. Other ongoing researches have been conducted to test statins 
part of combinatorial therapies as anti-tumor agents [15,16]. 
 Another interesting drug target is mevalonate kinase. Reports have shown that inhibiting 
mevalonate kinase by diphosphomevalonate blocks the growth of multiple-drug resistant 
 
Scheme 1.1 Chemical structures of statins. 
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Streptococcus pneumonia strain, but it did not affect the human mevalonate kinase [12]. Thus, it 
could be an antimicrobial target for treating parasitic infections. Mevalonate diphosphate 
decarboxylase can also be considered as an uprising drug target since the structures have been 
determined and various inhibitors have been developed [10,17,18]. 
 An alternative pathway was recently discovered to substitute for the mevalonate pathway in 
some species: the 2C-methyl-D-ery-thritol 4-phosphate (MEP) pathway [6,19]. MEP pathway 
has been studied for years. This pathway has been found to be widespread in many pathogens, 
including Bacillus anthracis, Clostridium difficile, Enterococcus faecalis, Escherichia coli, 
Pseudomonas aeruginosa, Helicobacter pylori, Neisseria gonorrhoeae [8,19]. Since this 
pathway does not exist in humans, it is of interest to study it in a great detail. 
 MEP pathway begins from condensation of pyruvate and D-glyceraldehyde-3-phosphate to 
form 1-deoxy-D-xylulose-5-phosphate (DOXP) by DOXP synthase (DXS) (Figure 1.1). DOXP 
is then reduced to form methyl-D-erythritol-4-phosphate (MEP) by DOXP reductoisomerase 
(IspC, DXR). MEP is subsequently catalyzed by CDP-ME synthase (IspD, CMS) to from 
4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol (CDP-ME). CDP-ME is then phosphorylated 
by CDP-ME kinase (IspE, CMK) to form 2-phospho-4-(cytidine 
5'-diphospho)-2-C-methyl-D-erythritol (CDP-MEP). CDP-MEP is then catalyzed by MEcPP 
synthase (IspF, MCS) to from 2-C-methyl-D-erythritol-2,4-cyclodiphosphate (MEcPP). MEcPP 
is then converted to hydroxymethylbutenyl (HMBPP) by HMBPP synthase (IspG, GpcE or 
HDS). HMBPP is then reduced to IPP and DMAPP by HMBPP reductase (IspH, LytB or HDR). 
The final products of this pathway IPP and DMAPP are isomerized by IPP isomerase (IPPI). 
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 The importance of this pathway as mentioned in the previous discussion is that it exists in 
some pathogens, but not in humans. It has drawn a lot of attention since the discovery of this 
pathway. Fosmidomycin and its derivtive FR-900089 (9 and 10, Scheme 2) from Jomaa’s group 
in Germany are the first class of drugs being identified as an effective antimalarial drug agent 
against DXR, which is the upstream enzyme in the MEP pathway [20]. Now, some clinical trials 
were initiated to test a combinatorial therapy with fosmidomycin and clindamycin (an 
anti-infective treating anaerobic bacteria) [21,22]. In addition, there are other potent drug targets 
in MEP pathway [6,19], such as GcpE (IspG) and LytB (IspH), will be discussed in the later 
chapters. 
1.2	   (E)-­‐4-­‐hydroxy-­‐3-­‐methylbut-­‐2-­‐enyl-­‐diphosphate	   Synthase	   (GcpE,	   IspG)	  
and	  (E)-­‐4-­‐hydroxy-­‐3-­‐methylbut-­‐2-­‐enyl-­‐diphosphate	  Reductase	  (LytB,	  IspH)	  
as	  Drug	  Targets	  
Note: some of the descriptions are partially adapted from our group’s publications [23,24]. 
GcpE and LytB are the two downstream enzymes in MEP pathway. Both GcpE and LytB 
are essential enzymes for survival, in bacteria as well as in malaria parasites. GcpE and LytB 
belong to a class of iron-sulfur cluster family. They contain a [4Fe-4S] cluster and three of the 
 
Scheme 1.2 Chemical structures of DXR inhibitors. 
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four irons bind to three highly conserved cysteines (Figures 1.2A,B). The only free iron named 
unique iron does not bind with other cysteines and plays a catalytic role. [23-27]. 
In LytB, HMBPP (12) is reduced to IPP (1) and DMAPP (2) in a ratio of ~5:1 by a 2H+/2e- 
process (Scheme 1.3) [26]. The mechanism of action of LytB is still under debate, including 
cationic, anionic, radical and diene intermediate [28-32]. By using inactive mutants E126A and 
E126Q from Aquifex aeolicus, we were able to trap all the possible intermediates by using 
CW-EPR, ENDOR and HYSCORE in a more convenient way [24,26]. Very recently, our group 
found some evidences to give an explanation of how the possible intermediates formed during 
LytB catalysis [24]. First, HMBPP binds to the unique iron via its terminal 4-OH group, forming 
intermediate I, an alkoxide (or alcohol) complex. On reduction, the 3-hydroxymethyl (3-CH2OH) 
group rotates away from the iron-sulfur cluster to from intermediate II, a π-complex, drawn 
alternatively as the metallacycle. This intermediate then loses an H2O molecule to form 
Intermediate III, an η3-allyl anion, which can also be drawn in its resonance form, an η1-allyl 
anion, bonded to the unique iron. Following the second e- and H+ delivery, the final products IPP 
and DMAPP are formed. 
Like LytB, the upstream enzyme GcpE also gains great interest [6,19]. GcpE (or IspG) 
catalyzes the conversion from MEcPP (11) to HMBPP (12, Scheme 1.4). It also utilizes a 4Fe-4S 
cluster with a unique iron that is not coordinated with any cysteine residues, but it binds to E350 
 
Scheme 1.3 Mechanism of LytB. 
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(in T. thermophiles), which is believed to be pulled away during catalysis (Figure 1.2A). Up to 
date, the mechanism GcpE function is still skeptical, and many mechanisms have been proposed 
during the past decade. In general, GcpE undergoes a 2H+/2e- reduction process likes LytB 
(Schemes 1.3,1.4), nonetheless, GcpE involves a series of ring opening and reduction steps. 
Specifically, Rohdich et al. [30] proposed that MEcPP underwent an OH- assisted isomerization 
(ring opening/ring closing) to produce an epoxide, which was then reduced to the alkene, 
HMBPP, probably via radical intermediates. Moreover, we and Nyland et al. [33] have made 
HMBPP epoxide (13, Scheme 1.5) and find it to be a good GcpE substrate, with the (2R, 3R) 
enantiomer (that would form from MEcPP). Recently, we proposed a new mechanism involving 
formation of ferraoxetane (14, Scheme 1.5): a 4-membered ring containing a Fe-O-C-C fragment 
[27]. In addition, we concluded the conformation of ferraoxetane and might be able to deduce the 
detailed catalytic mechanism [23]. 
Since GcpE is a very important drug target, it is of great interest to investigate its structures, 
 
Scheme 1.4 Mechanism of GcpE. 
 
Scheme 1.5 Possible GcpE reaction intermediates. 
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catalytic mechanism as well as inhibitor design. In our group, we found some of the alkyne 
(propargyl) diphosphate having inhibition against E. coli GcpE [27]. The propargyl group binds 
to the fourth unique iron [27]. Recently, there are two apo-GcpE crystal structures from Aquifex 
aeolicus and Thermus thermophilus being released [34,35]. Crystal structure of either AaGcpE 
(PDB ID code: 3NOY) or TtGcpE (PDB ID code: 2Y0F) shows they belong to a two-domain 
system with high structural homology (Figure 1.3A). There are two monomers bound together as 
a dimer. Inside each monomer, connected by a small (4 residues) linker. The first domain, called 
the A-domain (close to the N-terminus), is structurally similar to the TIM barrel in 
dihydropteroate synthase (DHPS); the second domain (close to the C-terminus), named the 
B-domain, is a 4Fe-4S cluster containing domain that is structurally similar to sulfite reductase 
(Figure 1.3B). The iron-sulfur cluster in the B-domain is close to the entry to the TIM barrel in 
the second molecule in the dimer. Since these two crystal structures are merely apo-structures 
(without ligand bound information), they can only provide us very limited information how it 
catalyzes and how the ligands bind.  
Very recently (a month before I started writing the dissertation), Rekittke et al. determined a 
closed form crystal structure of TtGcpE bound to the substrate MEcPP [36]. Interestingly, this 
complex structure forms a closed conformation with a ~60°˚ rotation of the Fe4S4 domain. In this 
case, the iron-sulfur cluster domain moves closer to the TIM barrel domain to make it as a closed 
conformation. The diphosphate group of MEcPP binds to positive charged Arg and Lys residues. 
In addition to the C3 oxygen binds to the unique iron to form an initial binding state.  
To sum up, GcpE is especially an interesting drug target to study its mechanism of action 
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and inhibition. This dissertation covers the very first attempt on achieving the domain 
interactions of GcpE protein and how the residues behave in substrate binding even before the 
first MEcPP bound structure came out. 
1.3	   Farnesyl	   Diphosphate	   Synthase	   and	   Geranylgeranyl	   Diphosphate	  
Synthase	  as	  Drug	  Targets	  
 Malaria is endemic in Africa, Asia, and South America. According to the latest Malaria 
World Report, there are ~250 million cases each year and the total death toll is ~2-6 million [37]. 
The World Health Organization (WHO) has declared malaria as one of the major diseases that 
needs to be controlled in this century. 
 The Plasmodium strains that cause malaria are Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale and Plasmodium malariae. The most lethal strain among the 
Plasmodium family is Plasmodium falciparum. Plasmodium has a complicated life cycle:  
Plasmodium parasites have two hosts: mosquitos and humans. After parasites invade the human 
host, then travel to the liver where they rapidly reproduce. This is called liver stage disease 
although there are no signs of infection. Once the parasites have proliferated, they enter the 
bloodstream and cause blood stage disease, in which they invade red blood cells and consume 
hemoglobin [38].  In this stage it generates tens of thousands of parasites-infected cells which 
travel through the bloodstream and infected individuals start to feel sick. Without treatment, 
death can occur within one to two weeks after infection.  
 There are several malaria treatments being used over years. Quinine was the first drug 
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that was proved to be effective, followed by chloroquine (15, Scheme 1.6). Both quinine and its 
derivatives inhibit the formation of hemozoin. When malaria parasites invade human, they digest 
hemoglobin as their energy source. This produces free heme which in turn generate reactive 
oxygen species (ROS). This is toxic to the parasite, so it is polymerized to hemozoin, which is 
non-toxic. Quinine and chloroquine (16) are believed to prevent heme polymerization, inhibiting 
the formation of hemozoin [39], so the parasites are killed by ROS. Later drugs include 
dihydrofolate-reductase inhibitors (17, sulfadoxine) and artemisinin (18) are now formed to all 
these drugs [40,41]. Unfortunately, Quinine- and chloroquine-resistant malaria parasites are 
found everywhere and more recently, artemisinin-resistant parasites have found in Cambodia and 
Thailand [42]. In order to effectively treat malaria, there is therefore an urgent need to find new 
targets and new inhibitors (drug leads that can be developed into drugs). 
 One attractive target area is isoprenoid biosynthesis. In human, isoprenoid biosynthesis 
leads to formation of cholesterol, a main component in human cell machineries [43]. In addition, 
protein prenylation is a crucial process in cell signaling and in Plasmodium, farnesyl transferase 
(PFT) is an important drug target with inhibition of PFT leading to Plasmodium cell death 
[44,45]. However, the permeability of these inhibitors limits their efficacy in vivo. 
 In Plasmodium spp. and in most pathogenic bacteria, only the nonmevalonate pathway 
 
Scheme 1.6 Chemical structures of listed antimalarial drugs. 
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is present, which is not present in humans. Enzymes in this pathway are good drug targets since 
blocking IPP (1) and DMAPP (2) formation is lethal [46-48]. Likewise, inhibiting the enzyme 
that condenses IPP and DMAPP to form FPP (21, Scheme 1.8) and GGPP is also a potential drug 
target (Figure 1.4). In Plasmodium spp., FPP and GGPP are made in a single dual-functional 
enzyme, geranylgeranyl diphoshate synthase (GGPPS). P. vivax GGPPS (PvGGPPS) is 
potentially inhibited by common FPPS inhibitors, such as zoledronate (19, ZOL) and risedronate 
(20) with IC50 values of 47nM and 43nM, respectively (Scheme 1.7). According to the multiple 
sequence alignment of FPPS and GGPPS from various organisms [49], PvGGPPS has 35% 
sequence identity against human FPPS (HsFPPS) and 21% sequence identity against human 
GGPPS (HsGGPPS). Structural alignment shows a 3.5Å RMSD against HsFPPS and a 4Å 
RMSD against HsGGPPS. PvGGPPS is an all-alpha protein (Figure 1.5A). In the ZOL/IPP 
complex structure (Figure 1.5B), the ZOL occupies the FPP/GPP site, which is the ionization site. 
It consists of two sets of DDXXD domains which are coordinated with Mg2+. In the IPP site, 
there are several positively charged residues surrounding the diphosphate group of IPP. In the 
product GGPP/PvGGPPS complex structure, the diphosphate group of GGPP occupies the IPP 
site, while the tail of GGPP occupies the tail of the FPP/GPP site, which is mapped with part of 
 
Scheme 1.7 Chemical structures of selected PvGGPPS inhibitors. 
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the imidazole ring of ZOL. Unfortunately, the common bisphosphonates are inactive in cells (or 
in vivo), so we need to develop compounds that penetrate cell membrane making them more 
effective [48]. 
The protein homolog in humans, HsFPPS, has been identified as a validate drug target for 
years [7,50-53]. Blockage of FPP formation by inhibiting HsFPPS protein contributes in treating 
various diseases such as osteoporosis, Paget’s disease, multiple myeloma as well as killing 
cancer cells [54,55]. Bisphosphonate is one of the most promising classes of drugs against 
HsFPPS. So far, there are many bisphosphonate-related drugs in the clinical use for treating 
osteoporosis. Blocking FPPS enzyme catalysis further stops the protein prenylation in osteoclast, 
leads to the apoptosis of osteoclast cells [54]. Moreover, inhibition of HsFPPS results in large 
accumulation of upstream substrates IPP and DMAPP, which has been reported to induce the 
formation of cytotoxic ATP analog, ApppI [56-58]. Formation of ApppI stops the tumor cell 
growth in breast cancer. In addition, inhibition of FPPS stimulates human Vϒ9Vδ2 T cell 
expression and prompts the immune response to tumor killing [59-74]. 
 Crystal structure of HsFPPS shares a high homology with PvGGPPS (Figure 1.6A). It also 
contains DDXXD domains as allylic site to bind FPP and the homoallylic site to bind IPP 
 
Scheme 1.8 Catalytic mechanism of FPPS. 
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(Figures 1.6B,C). It triggers the similar mechanism as PvGGPPS as described above (Scheme 
1.8). With superposition of all different classes inhibitors (bisphosphonate and allosteric site 
inhibitors) with substrates FPP and IPP, it shows the bisphosphonate binds to the FPP site and 
some potent non-bisphosphonate inhibitors bind to the allosteric site (Figure 1.6C). 
 In summary, both PvGGPPS and HsFPPS are poential drug targets for treating various 
diseases and the susceptible allylic (FPP) and homoallylic (IPP) sites are of interest to develop 
more potent drug leads. 
1.4	  Research	  Strategies	  
1.4.1	  Studying	  the	  Mechanism	  of	  Action	  and	  Inhibition	  of	  Bacterial	  and	  Plant	  GcpEs	  
Bacterial GcpEs, e.g. A. aeolicus and T. thermophiles, have a two domains system. 
A-domain is supposedly responsible for substrate binding and initial catalysis due to the large 
distribution of positive charged residues and B-domain governs the major catalytic event with 
association of iron-sulfur cluster. First, it is imperative to understand which residues are 
important for substrate/intermediate binding and which residues are essential for catalysis. 
Second, the crystal structure indicates the positions of these two domains and how the two 
domains interact with the neighboring domains. However, there is no such evidence to show how 
they are in action. Therefore, some critical evidences are needed to support the hypotheses.   
From the analysis of the primary sequences between bacterial (A. aeolicus and T. 
thermophiles) and plants or malaria (A. thaliana or P. falciparum) GcpEs by using ClustalW 
shows a degree of difference between these two homologs. A. thaliana or P. falciparum GcpEs 
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have additional ~30kDa insertion (Figure 1.7, red box) between TIM domain (Figure 1.7, cyan) 
and iron-sulfur domain (Figure 1.7, yellow). Since the additional domain is not included in 
bacterial GcpEs, the function of the extra domain still needs to be elucidated. Some speculations 
suggest the middle domain might play a role in catalysis [75]. Therefore, it is of interest to study 
the structure of the middle domain from one of the organisms. 
In this project, I began the investigation to use T. thermophiles GcpE as the main template 
(NCBI protein accession number AA021364). The first mission is to make selective mutations 
across the two domains to see whether or not they will have any influence on the binding or 
catalysis. In order to do this, it is important to determine the desired mutants since there were no 
structural information from either bacterial or plant, or any kind of GcpEs were available at that 
moment. Thus, we first applied some bioinformatics tools in our project. Combined with Jpred3 
[76] and SCORECONS [77] gave us a very reliable list based on the multiple sequence 
alignment together with conservation scores of various GcpE protein sequences. After pursuing 
knocking out individual residues and obtaining the activity results, these results were further 
mapped onto the modeled closed form GcpE with the substrate and reaction intermediate “X” to 
study the importance of those residues if the structural information is available. If the structural 
information is not achievable, it is preferred to run several modeling servers (Phyre2 [78], 
I-TASSER [79,80], MODELLER [81], etc) to obtain the most reliable GcpE model for further 
study. 
Second, I made various constructs with mutation on both domains to study the two domain 
interactions. The experiments were carried out: (1) Co-expressing two single-site mutants from 
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each monomer and presumably it will form a stable dimer; (2) Making a DUET construct with 
two single-site mutants in one vector. It might enhance the protein folding efficiency and 
increase the chance of achieving more stable dimerized protein. All the catalytic activity 
measurements were using MEcPP as substrate and dithionite as reducing agent. Activity 
measurement were detected by using methyl viologen as indicator monitored at λ=732nm. 
Identification of reaction interaction or product was investigated by using Continuous Wave 
Electron Paramagnetic Resonance (CW-EPR) and Hyperfine Sub-level Correlation (HYSCORE) 
EPR experiment. All procedures are done under anaerobic condition. EPR experiments were 
done at 15K. 
Since the crystal structures of GcpE are not easy to achieve, we applied the electron 
microscopy to study the middle domain of AtGcpE. The EM image gave us the information how 
the middle domain looks like and how it orients to form a complete three domains GcpE.  
1.4.2	  Development	  of	  Potent	  Homoallyic	  Site	  Inhibitors	  Against	  PvGGPPS	  
Recently, we collaborated with the Institut Pasteur Korea (IP Korea) to screen ~850 of our 
bisphosphonates and related compounds [48]. We found some of our bisphosphonates have 
strong inhibitory activity in vivo cell assays (blood stage form), compounds such as BPH-703 (23, 
an analog of zoledronate), BPH-816 (24) and BPH-315 (22, IC50 690nM, 470nM and 1.2µM, 
respectively, Scheme 1.9). In addition, the enzymatic assay of BPH-703 showed an IC50 of 
 
Scheme 1.9 Chemical structures of potent PvGGPPS inhibitors. 
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1.8µM, similar to the IC50 of zoledronate, and this compound has low toxicity against several 
human cell lines (average IC50 across MCF-7, SF268 and NCIH-460 cell lines is 244uM). In vivo 
mouse testing in the presence of BPH-703 shows no sign of parasitemia within the first 15 days. 
In order to prove the BPH-703 really targets the PvGGPPS, parasite growth was restored in the 
addition of geranylgeranyl alcohol (GGOH) and farnesyl alcohol (FOH).  
 In order to investigate the interaction between our potent PvGGPPS inhibitors and 
PvGGPPS, it is important to obtain atomic resolution structures of their complexes. I recently 
successfully co-crystallized BPH-703 with PvGGPPS, and solved the structure (PDB ID code 
3M9R) [48]. 
 Remarkably, the binding pose of BPH-703 aligned identically with the zoledronate/IPP 
complex structure (Figure 1.8A). The ligplot shows that it has several interactions with 
surrounding residues and Mg2+ (Figure 1.8B). The bisphosphonate head group and the middle of 
imidazole ring align with zoledronate, which are located in the GPP/FPP allylic site. Interactions 
between Lysine-243 and other residues suggest that nitrogen is located in the proposed 
carbocation-binding site [50]. The lipophilic alkyl chain occupies the hydrophobic cavity and 
stabilizes the complex (Figure 1.8C). The main difference between the zoledronate and BPH-703 
structures is the presence of the long (12-carbon) alkyl chain, which increases the potency of 
inhibitor, in cells [48]. 
 The catalytic mechanism of PvGGPPS is straightforward [82]. It consists of several 
ionization-codensation-elimination reactions in which the double bond of IPP attacks the C1 
atom of the dimethylallyl/geranyl/farnesyl carbocation. The carbocation intermediate is predicted 
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to be stabilized through electrostatic interactions with a Mg2+ ion bound diphosphate moiety, and 
through interaction with surrounding polar residues [50].  In the zoledronate/IPP complex 
structure, there are two binding sites (Figure 1.5B). The bisphosphonate head group of BPH-703 
occupies the GPP/FPP binding site. The second site is called the IPP binding site, in which the 
IPP diphosphate group coordinates with two Arg and one Lys. The question arises: since there is 
a large space extending from the IPP binding site to the GPP/FPP binding site, is it possible to 
accommodate a single molecule which can bind to both sites?  
 In recent work, our group found that some benzoic acids derivatives have good 
inhibitory effect against another prenyl synthase, dehydrosqualene synthase or CrtM [83]. 
Although CrtM is a “head-to-head” prenyl synthase and is distinct from “head-to-tail” prenyl 
synthases such as PvGGPPS [84], both molecules utilize the same substrates, FPP (21). We 
therefore screened ~200 molecules developed as CrtM inhibitors against PvGGPPS and found 
some of these molecules had inhibitory effects against PvGGPPS. Although they have low 
activities, it offers a starting point for lead optimization. One of the CrtM inhibitor leads found 
was a farnesyl thiosalicylic acid (Salirasib, 25, Scheme 1.10). Salirasib has a farnesyl chain 
attached to a benzoic acid, so it seemed probable that this compound and its analogs must bind to 
PvGGPPS. They do, but surprisingly, the binding poses were not what we expected as the 
 
Scheme 1.10 Chemical structures of Salirasib. 
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benzoic acid binding to the GPP/FPP site, similar to other bisphosphonates. 
Since the crystallization of PvGGPPS with inhibitor bound complex structure is a routine 
experiment [48,49], it is feasible to achieve various benzoic acids in complex with PvGGPPS to 
deeply investigate the interactions between those benzoate and PvGGPPS. Moreover, it might be 
possible to utilize those complex structures to make more potent and selective inhibitors against 
PvGGPPS and improve in vitro cell activity, or even in vivo.  
1.4.3	  Chain	  Length	  Variation	  of	  Lipophilic	  Bisphosphonate	  Against	  HsFPPS	  
 The BPH-703 (23) as reported had good in vitro and in vivo activity against PvGGPPS [48]. 
Thus, we have great interest to test this inhibitor against other FPPS proteins. Surprisingly, we 
found it has sub-micromolar inhibition against HsFPPS. We have synthesized various chain 
lengths of BPH-703 series with or without the hydroxyl group on the bisphosphonate group and 
tested against HsFPPS. We also tested those inhibitors against γδ T cell activation by our 
collaborator Prof. Morita’s group. The results of enzymatic assays were compared with the 
results of cell assay. 
Moreover, one of the potent BPH-703 series inhibitors was co-crystallized with HsFPPS to 
investigate the detailed interactions with the protein and how the long chain lipophilic 
bisphosphonate performed along with the protein. 	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1.5	  Figures	  
Figure 1.1 Mevalonate and non-mevalonate (MEP) pathway. 
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Figure 1.2 Iron-sulfur cluster in GcpE (IspG) and LytB (IspH). (A) Fe4S4 position in Thermus 
thermophilus GcpE (TtGcpE); (B) Fe4S4 position in Aquifex aeolicus LytB (AaLytB). 
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Figure 1.3 Overall structure of AaGcpE and TtGcpE. (A) Superposition of crystal structures of 
AaGcpE and TtGcpE. Orange: AaGcpE; cyan: TtGcpE; (B) Domain distribution and packing of 
TtGcpE. A: TIM barrel (N-terminus); B: iron-sulfur cluster domain (C-terminus). Cyan 
represents for one monomer and pink represents for another monomer. 
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Figure 1.4 Isoprenoid biosynthesis and potential targets. Bisphosphonates inhibit FPPS/GGPPS 
as well as the long-chain prenyl synthases involved in quinone biosynthesis, protein prenylation, 
and dolichol formation; phosphonosulfonates and related species inhibit head-to-tail prenyl 
transferases such as squalene and dehydrosqualene synthase and may target phytoene synthase in 
Plasmodium spp.; cationic nitrogen-containing species such as Ro48-8071 inhibit diverse prenyl 
transferases. DXR, deoxyxylulose-5-phosphate reductoisomerase; FTI, farnesyl transferase 
inhibitor; PSY, phytoene synthase; CtrM, dehydrosqualene synthase; OPPS, octaprenyl 
diphosphate synthase; MEP, methylerythritol phosphate; and FTase, protein farnesyl transferase. 
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Figure 1.5 Crystal structure of PvGGPPS. (A) Superposition of two PvGGPPS crystal structures 
in complex with ZOL (purple, PDB ID code 3LDW), IPP (green, PDB ID code 3LDW) and 
GGPP (yellow, PDB ID code 3PH7); (B) Local interaction of (A) with DDXXD domains, Mg2+ 
and positive charged residues in IPP site. 
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Figure 1.6 Binding sites architecture of HsFPPS. (A) Superposition of HsFPPS (cyan, PDB ID 
code 3N6K) and PvGGPPS (pink, PDB ID code 3RBM); (B) Electrostatic surface of HsFPPS 
with superposition of three substrate/inhibitors. (C) Close-look of (B) with representation of 
three inhibitor/substrate binding sites. HsFPPS/ZOL/IPP is from PDB ID code 2F8Z and 
HsFPPS/NOV823 is from PDB ID code 3N6K. 
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Figure 1.7 Multiple alignment result of GcpE proteins. Blue box represents for the A-domain 
(TIM barrel), red box represents for insertion domain of PfGcpE and AtGcpE, and yellow box 
represents for B-domain (iron-sulfur cluster domain). 
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Figure 1.7 Continued 
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Figure 1.8 Crystallographic structure of the lipophilic zoledronate analog BPH-703 bound to 
PvGGPPS. (A) BPH-703 (cyan, Protein Data Bank (PDB) ID code 3RBM) bound to PvGGPPS 
superimposed on zoledronate (ZOL) structure (yellow, PDB ID code 3LDW ). Conserved Asp in 
red; Arg/Lys in blue. Note Val-153(B), Val-156(B), and Leu-157(B) are from the second GGPPS 
molecule in the dimer. (B) Ligplot representation of local interactions of BPH-703. (C) Two 
BPH-703 bound to the dimer with Leu-157 (orange) below the inhibitor. 
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Chapter 2: Structure, Function and Inhibition of the Two- and 
Three-domain 4Fe-4S IspG Proteins 
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2.2	  Introduction	  
IspG ((E)-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate (HMBPP) synthase; EC1.17.7.1, 
(also known as GcpE) is a 4Fe4S cluster-containing protein (1) involved in isoprenoid 
biosynthesis in the methylerythritol phosphate (MEP) pathway (2-4).  It converts 
2-C-methyl-D-erythritol-2,4-cyclodiphosphate (MEcPP, 1) to HMBPP (2) which is then 
converted by a second 4Fe4S protein, IspH (also called LytB), to form isopentenyl diphosphate 
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(IPP, 3) and dimethylallyl diphosphate  (DMAPP, 4) in a ~5:1 ratio (3).  IspG is found in most 
bacteria as well as in malaria parasites and plants and, since it is essential for pathogen survival 
and is not produced by humans, is of interest as a drug target.  There are, however, two different 
types of IspG.  In most bacteria, IspGs contain two domains: an N-terminal catalytic domain (A) 
and a C-terminal 4Fe4S reductase domain (B), Figure 2.1A (5).  In plant and in malaria parasite 
IspGs, the A,B domains are again present, but there is in addition a third or insert domain, A*, 
located between the A,B domains, Figure 2.1B (5, 6).  This insert domain is also found in some 
photosynthetic green sulfur bacteria, algae, mosses, as well as in numerous intra-cellular 
pathogens such as Babesia bovis, Theileria parva, Chlamydia trachomatis and Leptospira 
interrogans, but the structure and function of this domain is not known. 
 A direct role in catalysis, that is as one involving processing of the MEcPP substrate, 
seems unlikely since as shown in Figure 2.7 there are few conserved residues in the A* domain 
between 10 plant, malaria and bacterial 3-domain IspGs, while in the 2 domain proteins there are 
large numbers of conserved residues that are essential for catalytic activity, as shown via 
site-directed mutagenesis (7).  This leads to the idea that the A* domain might play a more 
passive, structural role, linking the two (A,B) “catalytic” domains together for catalysis.  If this 
view is correct, then it would be predicted that all A* domains – even though they lack high 
 
Scheme 2.1 Chemical structures of MEcPP (1), HMBPP (2), DMAPP (3) and IPP (4). 
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sequence homology, would adopt a similar structure in order to link the A and B domains 
together.  Likewise, it would be predicted that the EPR (as well as ENDOR, HYSCORE) 
spectra of the 2 and 3 domain proteins containing the reactive intermediate “X” (8) (as well as 
bound inhibitors) would be very similar since the A* domain is not directly involved in ligand 
bonding. 
 In recent work, x-ray crystallographic structures of IspG from Aquifex aeolicus and 
Thermus thermophilus (called here AaIspG and TtIspG) have been reported (7, 9) and these 
provide important clues as to the likely nature of the 3 domain proteins. The structure of the (A,B) 
2 domain protein AaIspG is llustrated in Figure 2.1C and consists of a dimer of IspG molecules.  
There are two domains in each monomer, with the N-terminus (A, blue) having close structural 
homology with the TIM (triose phosphate isomerase) barrel in dihydropteroate synthase, the 
C-terminus (B, orange) having close structural homology to sulfite/nitrite reductase (7, 9).  
Based on these results, it was proposed that the dimer (AB)2 is the catalytically relevant structure, 
with the C-terminus (4Fe4S cluster, B) of one molecule in the dimer interacting with the open 
mouth of the TIM barrel (A) in the second molecule in the dimer in such a way that the MEcPP 
substrate is trapped between the two domains, interacting with both.  As can be seen in Figure 
2.1D, a ConSurf (10) analysis reveals many highly conserved residues (dark pink) in the TIM 
barrel and at the A/B interface in the dimer. IspG could, however, also in principle function as a 
monomer (or higher multimer), although the dimer model is more satisfying since the distance 
between the center of the TIM barrel is only ~15Å from the 4Fe4S cluster (in AaIspG; ~20Å in 
TtIspG) as compared with a ~50Å distance to the TIM barrel in the same chain, and can be “bent” 
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to be even closer (9), Figure 2.1E,F.  These observations raise then two key questions: first, is 
the catalytic dimer model in fact correct?  Second, if it is, might this structure suggest a role of 
the insert domain (A*) in the plant, malaria and other 3-domain proteins?   
 If the three-domain IspGs function as dimers, then the observation that the highly 
conserved catalytic residues are primarily found in the A and B domains would require an 
architecture along the lines of that illustrated in Figure 2.1G, in which there would be no obvious 
role for the insert (A*) domain. If, on the other hand, the three-domain catalytically-active 
structures are monomeric, then a structural organization similar to that shown in Figure 2.1H 
could be envisaged, in which the insert domain would play a similar “structural” role to the TIM 
barrels in the bacterial IspGs in which there is a large A/A contact patch in the (AB)2 dimer 
interface (7, 9) that stabilizes the protein’s structure. The AA* domain would thus act as a rigid 
rod with the B domain moving onto the rod to effect reduction of the reaction intermediate, then 
off, to permit product release: a “cup-and ball” model.   
2.3	  Results	  and	  Discussion	  
In the following, we focus first on the structure and function of the two-domain bacterial 
IspGs from Aquifex aeolicus and Thermus thermophilus, PDB ID codes 3NOY and 2Y0F. In 
particular, we wish to know if these proteins function in solution as monomers or dimers since a 
better understanding of the structure and function of these proteins might lead to a better 
understanding of the structure and function of the 3 domain proteins.  We then use a 
combination of spectroscopy and quantum chemistry to investigate ligand-binding to both 2 and 
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3 domain proteins – to determine if the same reactive intermediates and patterns of inhibition are 
found – probing functional equivalence. Finally, we use these results together with 
computational predictions and electron microscopy (EM) to develop a model for the A* insert 
domain which we propose is a second TIM barrel, leading to an AA*B structure prediction that 
is consistent with the observation that a plant (Arabidopsis thaliana) IspG, AtIspG, functions as a 
monomer. And finally, we consider briefly possible reasons for the evolution of the 3 domain 
structure. 
2.3.1	  IspG	  Quaternary	  Structures	   	   	  
The two-domain bacterial IspG proteins exist as dimers in the crystalline solid state, but we 
wished to determine if they exist as catalytically active dimers, in solution, as well as determine 
whether the three-domain enzymes function as monomers or dimers, since this should help 
clarify the structural proposals illustrated in Figure 2.1G,H.  To test the hypothesis that a 
bacterial IspG (TtIspG) functions as a dimer, we carried out a series of experiments.  First, we 
used glutaraldehyde cross-linking combined with SDS-PAGE and mass spectrometry, to see if 
dimer formation occurs in solution.  Cross-linking results for oxidized as well as reduced 
TtIspG (to see if there might be any difference in protein-protein interaction due to cluster 
reduction) are shown in Figures 2.2A,B, together with results for lysozyme, as a control, Figure 
2.2C. These results clearly show that most IspG molecules present in solution are cross-linked 
after a 30 min incubation with glutaraldehyde, independent of redox state, while no dimer 
formation is found with lysozyme, even after 12 hours incubation, consistent with strong IspG 
dimer formation in solution, and only weak interactions in lysozyme. Mass spectrometry 
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confirmed these results. Second, the results of gel filtration experiments (Figure 2.2D,E) confirm 
that TtIspG exists in solution primarily as a dimer (MW= 94 kDa from experiment; 92 kDa 
expected for the dimer).  Next, we need to answer the questions: is catalysis effected by 
monomers, or by dimers, in the bacterial enzyme?  And if a dimer, is catalysis effected by 
individual molecules in the dimer (AB), or by both molecules in the dimer, (AB)2? 
 To answer these questions, we constructed TtIspG chimeras (ABmAmB) consisting of 
two catalytically inactive mutants in which there was a mutation (m) that blocked activity in 
either the TIM barrel (AmB), or the 4Fe4S cluster (ABm), the idea being that even though neither 
monomers nor homo-dimers would be active, chimeras or hetero-dimers would be active, since 
the TIM barrel domain in a 4Fe4S cluster domain mutant (ABm) could still interact with the 
4Fe4S cluster domain in the TIM barrel mutant (AmB).  But which mutants should we make?  
An obvious candidate for mutational analysis would be one of the Cys residues coordinated to 
the 4Fe4S cluster:  we used C297S (6).  We also need a TIM barrel mutant plus, ideally, an 
essential 4Fe4S domain mutant that does not prevent Fe-incorporation, since this might be more 
stable. To find suitable mutants, we used the SCORECONS program (11). We used a JPRED3 
(12) alignment based on TtIspG as input to SCORECONS finding (Table S1) that E232, in the 
TIM barrel (A), was the most essential residue, while N346, in the 4Fe4S cluster domain (B), 
ranked 3rd overall, Table S1. We thus made three single mutants:  E232A, C297S and N346A, 
none of which were active, Figure 2.2F (columns b, c, d), consistent with previous results for the 
equivalent E232 and C297 mutants in A. aeolicus (6, 7). 
 Initial attempts to generate chimeras or to facilitate hetero-dimer formation using a 
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mixture of two mutants (E232A + C297S), in the presence or absence of detergents, yielded no 
activity, perhaps because homo-dimer formation was too tight.  We thus co-expressed both 
mutants using His-tagged proteins, finding 52% (E232A/N346A) and 23% (E232A/C297S) 
activity, Figure 2.2F (e,f). This suggested that the catalytically-active forms arise from the two 
individual mutants–which themselves are inactive, supporting the catalytic dimer model for the 
two-domain, bacterial IspGs. 
 In order to obtain pure chimeras containing a 1:1 ratio of each mutant, we next used a 
Duet vector to co-express E232A (His)6/C297S (Strep-tag) and E232A (His)6/N346A (Strep-tag) 
proteins. After Ni-nitrilo-triacetic acid followed by Strep-Tactin affinity chromatography (13), 
we obtained chimeras (ABmAmB) containing a TIM barrel mutation in one chain and a 4Fe4S 
cluster-domain mutation in the second chain, as illustrated in Figure 2.2G. The two chimeras 
both exhibited ~50% activity Figure 2.2F (g,h). These results confirm that the TtIspG 
homo-dimer is the catalytically active species in solution, and form the basis for further 
experiments, with the A. thaliana protein. 
 With wild type AtIspG, initial results of size-exclusion chromatography indicated 
protein aggregation and low catalytic activity, so we used size-exclusion chromatography to 
isolate non-aggregated wild type AtIspG (Figure 2.2H). The fraction of the protein that eluted as 
a monomer (MW 74 kDa from experiment, Figure 2.2E, 82 kDa expected) was found to have 
good activity (~8 µmol min-1 mg-1), comparable to that obtained with E. coli IspG. In addition, 
there was no evidence for extensive dimer formation using glutaraldehyde cross-linking, the 
major effect being polymer formation (Figure 2.2I). Taken together, these results indicate that 
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AtIspG exists and functions in solution as a monomer, consistent with an AA*B structure, Figure 
2.1H, while the bacterial two domain IspGs function as dimers. 
2.3.2	  Protein-­‐Protein	  and	  Protein-­‐Ligand	  Interactions	   	  
At present, there are no crystallographic structures of the closed conformation of any 
bacterial IspG, so how the MEcPP substrate (and the reactive intermediate “X” (2)), the HMBPP 
product, as well as IspG inhibitors (2) bind, is uncertain.  We thus next explored whether 
computational docking might help answer some of these questions, with the two domain AaIspG. 
We first used the RosettaDock program (14) to dock the B domain (orange) of AaIspG to the A 
domain (blue), converting the open conformation (Figure 2.1C,D) to the closed form (Figure 
2.1E,F), then used Glide (15) to dock the MEcPP substrate (with or without Glu-350 bound to 
the 4Fe4S cluster). The only docking poses returned were with MEcPP bound to the TIM barrel 
with electrostatic interactions between the MEcPP diphosphate and R101, K176 and R232, 
Figure 2.8A. Based on the SCORECONS (11) conservation score ranking (Table 2.1), these 
residues are ranked as 20, 17 and 10 in terms of their conservation in a series of 310 IspG 
proteins.  We then used Glide followed by molecular mechanics to generate docked poses of the 
putative ferraoxetane intermediate “X” (16), as well as of the bound HMBPP product, Figure 
2.8B,C.  With “X,” binding was to R55, R101 and N103; with HMBPP, binding was to R55, 
R101, R128, R232 and K176, residues that are ranked 19, 20, 11, 10 and 17 in terms of their 
conservation score (Table 2.1). We then mutated R56, R141 and K204 in TtIspG (corresponding 
to R55, R128 and K176 in AaIspG) to Ala, finding in each case a ~95% reduction in catalytic 
activity, Table S1. R55, R101 and R128 have been shown to be essential for catalysis in A. 
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aeolicus IspG by Lee et al. (7) and R141 (Thermus numbering) is essential for survival in 
Salmonella enterica (17). So, based on the docking results, their conserved nature (Table 2.1) 
and the mutagenesis results, these residues are all likely to be involved in MEcPP, reactive 
intermediate or HMBPP product binding, via their diphosphate groups, while the reactive 
intermediate and HMBPP product also interact directly with Fe via Fe-O and/or Fe-C bonds, the 
HMBPP O-1 Fe interaction being similar to that seen with HMBPP binding to IspH (18).    
2.3.3	  Spectroscopy	  and	  Quantum	  Chemistry	   	   	  
We next investigated whether we could detect the reactive intermediate “X” that forms from 
MEcPP (2) with wild-type bacterial IspGs, in the mutant and chimera bacterial proteins, as well 
as in the three domain IspG from A. thaliana, using EPR, ENDOR and HYSCORE spectroscopy. 
With the C297S TtIspG protein, there is no 4Fe-4S cluster and hence, no signal. With the E232A 
mutant, the (brown) sample has the UV-VIS spectrum expected, but we were unable to detect “X” 
using either MEcPP or HMBPP-epoxide as substrate, consistent with a key role for E232 in 
catalysis. However, with the E232A/N346A chimera, we observed the EPR spectrum of “X” 
arising from the MEcPP substrate, Figure 2.3A, and at longer incubation times, this intermediate 
converted to the bound-HMBPP product, Figure 2.3B.  Similar results were found in the EPR 
spectra of MEcPP bound to the plant IspG, Figure 2.3C,D, with both the reaction intermediate 
“X” as well as to the HMBPP product being detected. There are slight differences in the g-values 
between the bacterial and plant proteins but this is not wholly unexpected and it is clear that “X” 
forms in both cases, as does the bound HMBPP product. We also find that the 1H ENDOR 
spectrum of MEcPP bound to AtIspG (Figure 2.4A) is essentially identical to that of MEcPP 
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bound to E. coli IspG (2), with a ~12 MHz 1H hyperfine interaction for one of the C2′ methyl 
protons, proposed elsewhere to be located in a ferraoxetane ring (16). Likewise, the 13C 
HYSCORE spectra of [U-13C]-MEcPP bound to both TtIspG chimeras (Figure 2.4B,C) as well 
as AtIspG (Figure 2.4D) are essentially identical to those seen with EcIspG (2), again indicating 
the same reaction intermediate forms with both 2 and 3 domain proteins. There is also only a 
very small (~0.15 MHz) hyperfine coupling observed with 17O1 labeled X (Figure 2.4E), 
consistent with no direct Fe-O1 bonding. 
 Mechanistically then, it appears that MEcPP binds to the conserved Arg/Lys residues in 
the A domain and that the carbo-cation that forms on ring opening is located very close to the 
4Fe4S cluster domain, which then leads to formation of the reaction intermediate, X (2, 16). This 
intermediate is characterized by a large (~12 MHz) 1H hyperfine coupling constant for one of the 
C2′ methyl protons (16), and a ~17 MHz hyperfine coupling for the C2 carbon (16). To see to 
what extent it might be possible to predict these spectroscopic observables, we used density 
functional theory (DFT). The structural model used was 
[Fe4S4(SMe)3(-C(CH2OH)(CH3)-CH(CH2OH)-O-]2- (Figure 2.5A) with S=1/2. All calculations 
were performed with the Gaussian 09 program (19) using a Wachters’ basis 
(62111111/3311111/3111) for Fe, 6-311G(d) for other heavy atoms, 6-31G(d) for hydrogens, 
and the BPW91 functional, as reported previously (20).  
 We found good accord with experiment for the H2′, methyl protons, with computed 
hyperfine couplings of 9.1, 2.0, and 1.1 MHz for the three non-equivalent protons.  This large 
coupling is in good accord with experimental results (A(1H) ~12 MHz) and arises from the trans 
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(Fe-C-C-H torsion angle = 172°) proton, while the gauche protons have much smaller couplings 
(and geometry optimized torsion angles of 52, -67°) – similar to the observation of large 3J trans 
scalar couplings (mediated via Fermi contact interactions) in NMR spectroscopy.  Overall, there 
is a good correlation between the twelve computed hyperfine couplings determined with DFT 
and those determined experimentally, as shown in Figure 2.5A and Table 2.2, although there is a 
systematic error in the slope, due most likely to basis/functional deficiencies. The correlation 
coefficient, R = 0.87 is, however, very good. The computed spin densities are shown graphically 
in Figure 2.5B and show, as expected, that significant spin density is transmitted from the cluster 
to the H2′-trans proton (indicated with an arrow). The results of AIM (21) quantum chemical 
calculations (Table S2.3) indicate that binding to Fe is primarily electrostatic (∇ 2ρ(r)>0) with 
partial covalence (21), just as found in simpler systems such as [FeF6]3- and [Fe(CN)6]3-, Table 
S2.3. 
2.3.4	  Inhibitor	  Binding	   	   	  
We next briefly consider the topic of the inhibition of the bacterial and plant IspGs, of 
interest in the context of drug discovery as well as in the context of the equivalence of the 2 and 
3 domain protein structures.  In previous work, we investigated the inhibition of AaIspH (LytB) 
by a series of compounds, alkynes and pyridines linked to diphosphates or bisphosphonates (22), 
as well as two alkyne diphosphates that inhibited IspG (2), finding in both cases that the alkynes 
bound close to the 4Fe4S cluster.  Here, we tested 25 compounds (Figure 2.9) for IspG 
inhibition. As with IspH, only the alkyne diphosphates proved to be good IspG inhibitors. But 
how might they bind? 
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 In the case of IspH, there is a highly conserved SXN site that diphosphate (and 
malonate) ligands bind to (23), but are there any highly conserved residues in the 4Fe4S domain 
in IspG to which the alkyne inhibitor diphosphates might bind?  Based on the SCORECONS 
analysis (Figure 2.7), the only highly conserved (non-cluster-bound) residues in the 4Fe4S 
cluster domain are N346 and R302 (corresponding to N303 and R270 in the A. aeolicus protein).  
When mutated to Ala, there is only 0.75% wild-type activity for N346A (Table S1), and 3.9% for 
R302.  These residues are, however, ~10Å distant from each other, and it is not possible to dock 
a diphosphate group to them both. So, rather than the diphosphates binding to the 4Fe4S 
cluster-containing domain (B) as in IspH, it appears likely that the diphosphates interact with the 
Arg/Lys-rich cluster in the TIM barrel. This idea is supported by the computational docking 
results shown in Figure 2.7D in which the diphosphate group in an alkyne inhibitor (5, IC50=770 
nM TtIspG; Figure 2.9) binds to R55, R101, R128, K176 and R232. In addition, the results of a 
HYSCORE experiment with  [U-13C] propargyl diphosphate (6) bound to AtIspG (Figure 2.10) 
show a ~6 MHz hyperfine coupling (as with EcIspG), indicating that the side-chain binds close 
to the 4Fe4S cluster, in the B domain, just as in the two-domain bacterial IspGs. 
2.3.5	  The	  Insert	  Domain	  (A*)	  is	  a	  TIM	  Barrel	   	   	  
Finally, we propose a model for the three dimensional structures of the 3-domain IspGs 
using computational methods.  This approach has been successful with other prenyl synthases, 
in particular with the diterpene cyclases, where the use (24) of a variety of computational tools 
enabled successful prediction of the three-helical αβγ domain structures, recently confirmed by 
two crystallographic investigations (25, 26).  
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 The main questions of interest are:  what is the structure of the insert domain, A*?  
And how might it interact with the N-terminal (TIM barrel, A) and C-terminal (4Fe4S cluster, B) 
domains? To provide possible answers to these questions, we first used several different protein 
structure prediction programs (27-31) to make predictions of the structure of the insert domain, 
A*.  Remarkably, in all cases, the structure predictions for the A* insert domain converged to 
the known N-terminal TIM barrel fold (A) found in the two bacterial IspG structures (7, 9). A 
representative structure (using a ClustalW2 multi-sequence alignment and Modeller) (32, 33) is 
shown in Figure 2.6A for the A. thaliana (plant) IspG insert domain: results using other 
computer programs are shown in Figure 2.11.   
 Clearly, the observation that all structure predictions of the insert domains indicate a 
TIM barrel strongly suggests that the plant (and other 3 domain) enzymes contain two TIM 
barrels: the catalytic N-terminal A, and the insert A*. In addition, based on the proposals (7, 9) 
that bacterial IspGs function with the C-terminus (B) of one molecule in the dimer interacting 
with the N-terminus (TIM barrel, A) of the second molecule in the dimer, and that the major 
contacts between the two AB molecules involve hydrophobic interactions between helices 7 and 
8 in the two TIM barrels, it seemed likely that similar interactions might occur in the plant and 
other insert-domain-containing IspGs, so we next generated a simple three-dimensional model 
for IspG from A. thaliana, Figure 6B, in which the structures of all three domains were generated 
computationally using Modeller (33), then aligned (in MOE (34)) to the AaIspG structure.  
How A joins to A* and A* to B is not yet well defined.  Using a ClustalW2 alignment of ten 3 
domain IspGs, we then obtained the ConSurf prediction shown in Figure 2.6C in which, as 
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expected, the most highly conserved residues (dark pink) are at the AB interface while homology 
in the A* domain is low (white/blue, Figure 2.6C).  More importantly, this computational 
model is in good accord with electron microscopy (EM) results for AtIspG, constructed (35, 36) 
by aligning and combining two tomographic single particle reconstructions of negatively stained 
AtGcpE particles from low dose electron tomographic tilt series (Figure 2.12), as can be seen in 
the EM (grey) superpositions shown in Figure 2.6D. 
 If this structural arrangement is correct, it seems likely that the plant and other 3 domain 
IspGs may have originated via an initial gene fusion (A + B) to form a bacterial homo-dimer, 
(AB)2, followed by gene duplication, exon loss and recombination, eliminating one of the 4Fe4S 
clusters to form the (AA*B) proteins, as shown in Figure 2.6E.  But why?  That is – why are 
there 3 domain IspGs?  What is well known about IspG is that it is hypersensitive to oxygen (37, 
38) and when we inspect all of the organisms that employ 3 domain IspGs there is clearly a 
common feature – essentially all are subject to oxidative stress. In green plants, mosses and algae, 
reactive oxygen species are generated during photosynthesis and can be expected to contribute to 
breakdown of the 4Fe-4S clusters. In the Apicomplexan parasites P. falciparum and B. bovis, the 
parasites infect red blood cells where there is expected to be oxidative stress (due to O2 as well as 
other ROS), and with bacteria such as C. trachomatis and L. interrogans, these pathogens again 
infect mammalian host cells and are expected to be susceptible to host generated ROS. The 
possibility exists then that the additional TIM barrel may provide a degree of protection from 
host ROS by providing e.g. a higher protein/iron ratio. 
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2.4	  Conclusions	   	   	  
The results we have described above are of broad general interest since they clearly indicate, 
based on gel filtration chromatography, cross-linking, chimera formation and spectroscopy, that 
most-bacterial IspGs function as an unusual (AB)2 dimer in which a TIM barrel domain (A) of 
one chain interacts with the 4Fe4S cluster-containing domain (B) in a second chain to form the 
active site. In the case of IspGs from plants, algae, as well as malaria and other parasites, the A,B 
structural motifs are similar, but rather than a homo-dimer of four domains, we propose that 
there is TIM barrel insert domain (A*) that plays a primarily structural role. EPR, ENDOR and 
HYSCORE spectra indicate the same reactive intermediate forms with both two and three 
domain enzymes, with this intermediate binding to the 4Fe4S cluster, during catalysis. The most 
potent inhibitors of both two and three domain enzymes, alkyne diphosphates, also bind close to 
the 4Fe4S cluster, as evidenced by similar EPR/HYSCORE spectra, indicating the same 
mechanism of inhibition, proposed to be inhibitor binding to a “closed” form of the enzyme with 
the inhibitors binding to both the A and B domains. Overall, these results should be of help in 
inhibitor design, a topic of considerable interest in the development of novel anti-infectives that 
inhibit isoprenoid biosynthesis in most pathogenic bacteria, as well as in malaria and other 
Apicomplexan parasites. 
2.5	  Methods	  
(Note: ENDOR/HYSCORE experiments were done by Dr. Weixue Wang.) 
Pulsed ENDOR/HYSCORE spectra were obtained on a Bruker ElexSys E-580-10 FT-EPR 
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X-band EPR spectrometer using a Bruker RF amplifier (150W, 100 kHz–250 MHz, for pulsed 
ENDOR experiments) and an Oxford Instruments CF935 cryostat. Davies pulsed ENDOR used a 
three-pulse sequence (πmw − T-π⁄2mw − τ − πmw-τ-echo; π⁄2mw = 48 ns,with πRF applied during T). 
HYSCORE used a four-pulse sequence (π⁄2mw − τ-π⁄2mw − t1 − πmw − t2 − π⁄2mw − echo; π⁄2mw = 
16 ns), 256 points for both t1 and t2, each at 20 ns steps. Time-domain data were baseline 
corrected using a third order polynomial, then Hamming windowed, followed by zero-filling and 
2D-Fourier transformation. Additional details on protein preparation, enzyme assays, 
EPR/ENDOR/HYSCORE sample preparation, electron microscopy and compound syntheses are 
reported in the following Supplementary Methods. 
2.6	  Supplementary	  methods	  
2.6.1	  Homology	  Modeling	  
(Note: This part was done by Francisco Guerra.) 
Homology modeling was carried out using a variety of programs (1-7) to predict the 
structure of the A* insert domain in AtIspG.  To select the appropriate insert domain sequence, 
we first carried out a sequence alignment of all of the IspG proteins from different organisms 
shown in Table 2.1, assigning AtIspG insert region residues (amino acids 365-635 in AtIspG) to 
the A* domain.  We then submitted this sequence to the following homology modeling servers: 
FUGUE (1) (single sequence-structure homology modeling based on HOMSTRAD database 
similarities and environment specific amino acid substitution tables); I-TASSER (2) (de novo 
protein fold prediction); LOMETS (3) (structure prediction meta-threading server that 
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incorporates 8 different prediction programs into a final metric of fitness for the predicted 
structure); FFAS (4) (a profile-profile alignment and fold-recognition server that uses 
MODELLER for structure rendering); and @TOME (5) (a meta-threading server that ranks 
multiple homologous sequence alignments and again uses MODELLER (6) for structure 
rendering).  We also used ClustalW2 (7) to obtain a multiple sequence alignment comparing the 
A (comprising residues 1-364 of AtIspG) and A* (comprising residues 365-635 of AtIspG) 
domains for all organisms listed in Table S1.  This ClustalW2 multiple sequence alignment was 
then used to create a homology model of the AtIspG A* insert domain with MODELLER, using 
the A. aeolicus IspG (PDB code 3NOY) A-domain as a template.  All modeled domains were 
passed through DSSP (8) to standardize the assignment of secondary structures.  Additionally, 
the final models were assessed with the Verify3D structure evaluation server (9), ensuring that 
essentially all residues had positive scores.  For example, only amino acids 389-398 and 
427-454 of the AtIspG TIM barrel structure created from the ClustalW2-MODELLER-DSSP 
method had a negative Verify3D score, while the amino acids corresponding to helix 7 and the 
surrounding area (residues 589-619) had the highest scores.  All final 3 domain models were 
rigidly aligned, as described in the text, with MOE (10) and images were rendered with PyMOL 
(11).   
2.6.2	  Computational	  Docking	  
The closed conformation of TtIspG was calculated by using the RosettaDock server 
(http://rosettadock.graylab.jhu.edu/) (12). The top-ranked conformation was chosen and was then 
used for ligand docking. Initial docking poses for MEcPP, the ferraoxetane “X”, HMBPP and 7 
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were determined by using the Glide program (13). These docking results were then refined by 
using molecular mechanics in MOE (14). All figures were generated by using PyMOL (11). 
2.6.3	  Quantum	  Chemical	  Calculations	  
(Note: This part was done by Dr. Yong Zhang.) 
To investigate the electronic structure of the ferraoxetane intermediate “X”, we used density 
functional theory. The basic model was [Fe4S4(SMe)3(-C(CH2OH)(CH3)-CH(CH2OH)-O-]2- with 
S=1/2. The model was fully geometry optimized by using the Gaussian 09 program (15) with a 
Wachters’ basis (62111111/3311111/3111) for Fe, 6-311G(d) for other heavy atoms, 6-31G(d) 
for hydrogens, and the BPW91 (16, 17) functional, as used previously (18, 19). 
In addition, to further investigate the binding to Fe, we used Bader’s Atoms-in-Molecules 
(AIM) theory to help analyze some of the results.  For convenience, we give here a very brief 
overview of this approach. According to AIM theory, each nucleus in a molecule is surrounded 
by a region called an atomic basin that is bounded by a zero-flux surface in ∇ρ, the gradient of 
the charge density, that defines an atomic boundary. When two atoms share some portion of their 
surfaces, a line of maximum electronic charge density is formed between the nuclei, and at the 
point where the shared surfaces intersect this atomic interaction line there is a saddle point in the 
charge density, ρ(r), called a bond critical point. At this point, ρ(r) is at a minimum along this 
atomic interaction line and at a maximum in the plane perpendicular to this line. In this manner, 
AIM theory identifies a unique line of communication between two chemically interacting nuclei, 
and provides a unique point at which to probe or characterize the nature of the interaction. Every 
chemical bond has a bond critical point at which the first derivative of the charge density, ρ(r), is 
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zero (20, 21). The ρ(r) topology is described by a real, symmetric, second-rank Hessian-of-ρ(r) 
tensor, and the tensor trace is related to the bond interaction energy by a local expression of the 
virial theorem: 
Tr(Hessian) = ∇2ρ(r) = [2G(r) + V(r)] (4m/ħ2) 
where ∇2ρ(r) is the Laplacian of ρ(r), and G(r) and V(r) are electronic kinetic and 
electronic potential energy densities, respectively. Negative and positive ∇2ρ(r) values are 
associated with shared-electron (covalent) interactions and closed-shell (electrostatic) 
interactions, respectively. In the latter case, one can further evaluate the total energy density, 
H(r), at the bond critical point: 
H(r) = G(r) + V(r) 
A negative H(r) is termed partial covalence, while a positive H(r) indicates a purely 
closed-shell, electrostatic interaction (20-22). The bond critical point described above is also 
called a (3,-1) critical point, since it has three non-zero curvatures of ρ(r), one of which is 
positive and two of which are negative. This type of critical point is associated with every 
chemical bond. All critical point properties were calculated by using the AIM2000 program (23). 
As shown in Table S3, Fe-C/O bonding is similar to that found in other coordination complexes 
(24), that is an electrostatic interaction (∇2ρ(r)>0) with partial covalence (H(r)<0). 
2.6.4	  Mutagenesis	  and	  Chimera	  Formation	  
The pQE60-TtIspG plasmid was a gift from Drs. H. Jomaa and J. Wiesner. The TtIspG gene 
was then cloned as a C-terminal His-tag fusion into the pET29b vector with the forward primer 
5’-GACATATGGAAGGTATGCGTCGTCCGACCC-3’ and the reverse primer 
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5’-GGCTCGAGCGCTTTCGGCGCGAAACG-3’. Site-directed mutagenesis for each TtIspG 
mutant (using the pEQ60-TtIspG as a template) utilized the QuikChange II Site-Directed 
Mutagenesis protocols.. The C-terminal His-tag of the pQE60-N346A and pQE60-C297S 
mutants was further replaced by a C-terminal Strep-tag (forward primer: 
5'-GACCCATGGAAGGTATGCGTCGTCCGACCC-3'; reverse primer: 
5'-CGGAGATCTTTATTTTTCGAACTGCGGGTGGCTCCAAGCGCTCGCTTTCGGCGCGA
AACGCGTTTTCACGTAG-3'). The mutants E232A-(His)6, N346A-Strep tag and 
C297S-Strep-tag were cloned into a pRSF-Duet vector as pRSFDuet-E232A-(His)6/N346A-Strep 
tag and pRSFDuet-E232A-(His)6/C297S-Strep tag by using NcoI and SacI in the MCS1 (forward 
primer: 5'-GACCCATGGAAGGTATGCGTCGTCCGACCC-3'; reverse primer: 
GAGCTCTTATTTTTCGAACTGCGGGTGGCTCC) and NdeI and XhoI in the MCS2 (forward 
primer: 5'-GACATATGGCCTTCGCCCCAG-3'; reverse primer: 
5’-TATCTCGAGTCAGTGGTGGTGGTGGTGGTGCGCTTTCGGCGCGAAACGC-5’). 
2.6.5	  Protein	  Expression,	  Purification,	  Reconstitution	  and	  Activity	  Determination	  
The wild-type TtIspG, mutants or chimeras were transformed into BL21(DE3) competent 
cells together with pDB1282. The inoculated bacterial culture was then grown in 100 mL LB 
supplemented with 0.2 % glucose, 0.5 mM CaCl2, 1 mM MgCl2, 100 µg/mL ampicillin (Amp) 
and 50 µg/mL kanamycin (Kan). The inoculated culture was shaken at 260 rpm at 37 °C and 
incubated overnight, then transferred into 1L Luria-Bertani (LB) broth with 0.5 mM CaCl2, 1 
mM MgCl2, 100 µg/mL Amp and 50 µg/mL Kan. The 1L LB broth was shaken at 200 rpm at 37 
°C until the OD600 reached 0.3, at which time 0.05 % of L-arabinose was added to induce 
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biosynthesis of the Fe4S4 cluster. Once the OD600 reached 0.8, the temperature was lowered to 24 
°C and 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 0.4 mM ferrous ammonium sulfate 
and 0.5 % L-cysteine was added to facilitate holo-protein production. The culture was incubated 
overnight and the cell pellet collected by centrifugation and stored at -80 °C.  All purification 
steps were carried out anaerobically. The wild-type TtIspG and single residue mutants were 
purified by Ni-NTA chromatography in a glove box using wash buffer (50 mM Tris, 500 mM 
NaCl, 50 mM imidazole, pH 8.0), then eluted using 100% elution buffer (50 mM Tris, 500 mM 
NaCl, 500 mM imidazole, pH 8.0). The fraction containing the deep brown TtIspG fraction was 
collected and desalted using a desalting column with 100 mM Tris, pH 8.0. The TtIspG was 
frozen in liquid nitrogen and kept at -80 °C. Purification of the chimera TtIspGs was similar to 
the procedure used with WT or mutants, but required an additional Strep-Tactin purification step. 
The IspG fraction after eluting from Ni-NTA was loaded onto a Strep-Tactin column and eluted 
with elution buffer (100 mM Tris, 150 mM NaCl, 2.5 mM D-desthiobiotin, pH 8.0). 
Measurements of TtIspG activity were as described previously (25), and were carried out by 
using 0.5 mM MEcPP as substrate. Enzyme activity assays were conducted as described 
previously (2) in 96 well plates using a SpectraMax Plus 384 spectrophotometer. Expression and 
purification of EcIspG was carried out as described previously (18). 
(Note: The following part was done by Francisco Guerra.)  
The pQE-31 plasmid containing an N-terminal truncated (signal- and transit- peptide 
cleaved) AtIspG gene was co-transformed with the KanR pDB1281 plasmid in E. coli BL21 
(DE3) RIPL competent cells.  Inoculated E. coli were grown aerobically in 100 mL sterile LB 
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(50 µg/mL Amp, 25 µg/mL Kan, 11 µg/mL Chloramphenicol (Cam)) for 12 hours at 37 °C, 
shaking at 250 rpm.  A 50 mL inoculum was transferred to 1.5 L of sterile LB broth (50 µg/mL 
Amp, 25 µg/mL Kan, 11 µg/mL Cam) in 4 L flasks and shaken at 185 rpm at 37 °C.  At OD600 
~ 0.2, 0.5 g/L D-arabinose (to induce expression of pDB1281 genes), 200 µM FeCl3, and 1 mM 
L-cysteine were added to each 1.5 L LB flask, then grown at 37 °C with shaking at 185 rpm.  
At OD600 ~ 1.0, protein expression was induced by adding 1 mM IPTG to each flask.  The 
cultures were grown at 28 °C for 12-14 hours, shaking at 160 rpm.  Cells were harvested by 
centrifugation at 9000 rpm using an SLC-3000 rotor and a Sorvall Evolution centrifuge.  Cell 
pellets were stored at -80 °C for later purification. 
All steps for anaerobic purification of AtIspG were performed in a Coy glove box at 4 °C.  
The cell pellet was lysed with 10 mg/mL lysozyme (chicken egg white), 62 U/mL benzoase 
nuclease (purity > 90%), and 1 tablet/50 mL protease inhibitor cocktail, in a slowly stirred 
binding buffer (5 mM imidazole, 100 mM HEPES, 200 mM KCl, pH 7.6).  The cell lysate was 
sonicated for 90 sec at on/off intervals of 10 s / 20 s, respectively, then centrifuged at 4000 rpm 
in an F-34-6-38 rotor in a table-top Eppendorf 5804 centrifuge for 90 min.  The supernatant was 
filtered using a syringe-driven 0.45 µm filter, and loaded onto a nickel affinity column, and 
purified as follows. First, bound protein was washed with 100-200 mL 50 mM imidazole (100 
mM HEPES, 200 mM KCl, pH 7.6).  IspG was then eluted with 250 mM imidazole (100 mM 
HEPES, 200 mM KCl, pH 7.6) and concentrated using 10K-50K centrifugal filters.  The 
concentrated protein was then loaded onto a PD-10 desalting column, eluted with final buffer 
(100 mM HEPES, 200 mM KCl, pH 7.6), and concentrated by centrifugation.  All purified 
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protein batches were run on SDS-PAGE gels to verify purity. MALDI-TOF mass spectra of 
AtIspG exhibited a major peak at 82,247 Da.  A BioRad protein concentration assay was used 
to determine final protein concentration. Protein was stored at -80 °C for activity measurements 
and inhibition assay. 
Aerobic purification of AtIspG was followed by reconstitution and was found to be > 95% 
pure (to be compared with ~80-90% for the anaerobic system).  The aerobic system was used in 
the cross-linking, gel filtration chromatography, and electron microscopy experiments.  For 
aerobic purification, the cell pellet was aerobically lysed with 10 mg/mL lysozyme, 62 U/mL 
benzoase nuclease (purity > 90%), and 1 tablet/50 mL protease inhibitor cocktail in slowly 
stirred binding buffer (5 mM imidazole, 100 mM HEPES, 200 mM KCl, pH 7.6).  The cell 
lysate mixture was sonicated for 90 s at on/off intervals of 10 sec/20 sec, respectively.  The cell 
lysate was then centrifuged at 23000 rpm in a SA-300 rotor in a Sorvall Evolution centrifuge for 
60 min.  The supernatant was filtered with a syringe-driven 0.45 µm filter and loaded onto a 
nickel-charged FPLC column.  The protein was purified by Ni-NTA chromatography using an 
Amersham Pharmacia Biotech FPLC, at 4 °C.  The column was washed with 100 mL 50 mM 
imidazole (100 mM HEPES, 200 mM KCl, pH 7.6). Subsequently, IspG protein was eluted using 
a gradient of 50-250 mM imidazole (100 mM HEPES, 200 mM KCl, pH 7.6).  Fractions 
showing peaks on the Ni-NTA FPLC chromatogram were run on SDS-PAGE.  Only those 
fractions from a single peak that showed > 90% purity on SDS-PAGE were consolidated.  The 
combined fractions were then dialyzed overnight in 4 L of buffer (100 mM HEPES, 200 mM 
KCl, pH 7.6), to remove imidazole.  The dialyzed protein was concentrated using 10K-50K 
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centrifugal filters in an A-4-62 rotor in a table-top Eppendorf centrifuge, model 5810 R.  The 
Ni-NTA FPLC purified, dialyzed, and concentrated protein was then loaded onto a Hi-Prep 
26/60 Sephacryl S-200 HR column and purified by gel filtration chromatography using FPLC.  
The fractions showing peaks on the gel filtration FPLC chromatogram were then run on 
SDS-PAGE.  Only those fractions from a single peak that showed > 99% purity on SDS-PAGE 
were consolidated and concentrated by centrifugation.  This > 99% pure protein was then 
reconstituted, desalted, and concentrated. A BioRad protein concentration assay was used to 
determine final protein concentration.  Final protein product was stored at -80 °C. 
Reconstitution of aerobically purified AtIspG was carried out in a Coy glove box at room 
temperature.  Concentrations of > 300 µM AtGcpE were used for this procedure in order to 
keep the total volume small. The Ni-NTA FPLC purified, dialyzed, gel filtration FPLC purified 
AtGcpE was briefly degassed so as to remove as much O2 without removing buffer and altering 
the protein concentration.  While the protein was stirred at 400 rpm on ice, DTT slowly added 
to a final concentration of 4 mM.  Then, 9 molar equivalents of Na2S (9 moles Na2S to 1 mole 
protein) were slowly added.  The stirring speed was decreased to 100 rpm for 30 min between 
Na2S and FeCl3 additions, and raised to 400 rpm while adding each material.  After 30 min, 6 
molar equivalents of FeCl3 were added, very slowly.  After 30 min, 3 more molar equivalents of 
FeCl3 were added.  The 9 Na2S, 6 FeCl3, 3 FeCl3 molar equivalent additions and wait steps 
were repeated to give 18:1 final molar equivalents.  This volume was centrifuged in a 1.5 mL 
microcentrifuge tube for 10 min and transferred to a PD-10 desalting column.  The protein was 
eluted with the same final buffer (100 mM HEPES, 200 mM KCl, pH 7.6) and concentrated 
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using 50k MWCO microcentrifuge filters. A BioRad protein concentration assay was used to 
determine final protein concentration.  The 410 nm / 280 nm OD ratios for the reconstituted 
protein were 0.3–0.4.  
2.6.6	  Size	  Exclusion	  Chromatography	  
Oligomerization of both TtIspG and AtIspG was examined by using analytical gel filtration 
chromatography (Superdex 200 HR 10/30, GE Healthcare) on an AKTA FPLC system at a flow 
rate of 0.6 ml/min. The concentrations of each protein were between ~1 – 2 mg/mL. 
β-lactoglobulin (36.8 kDa), enolase (93 kDa) and alcohol dehydrogenase (150 kDa) were used as 
molecular weight standards. 
2.6.7	  Cross-­‐linking	  Experiment	  
Wild-type TtIspG was desalted twice to remove Tris by using phosphate buffered saline 
(PBS). 4 mg/mL wt TtIspG was then incubated with 0.05% glutaraldehyde at 25°C anaerobically, 
with or without dithionite. Reactions were incubated for 0 sec, 30 sec, 1 min, 5 min, 30 min, 1 
hour, or 12 hours, and were quenched by adding 100 mM Tris, pH 8.0. The reactions were then 
frozen in liquid nitrogen, and stored at -80°C. 10 µM AtIspG was incubated with degassed 
0.05% glutaraldehyde for 30 sec, 1 min, 5 min, 30 min, and 60 min, and cross-linking was 
stopped by adding 20 mM Tris.  The cross-linked products were again analyzed by using 
SDS-PAGE and MALDI-TOF mass spectrometry. Lysozyme was used a control for the 
cross-linking experiments. 
2.6.8	  Enzyme	  Inhibition	  
(Note: this part was done by Francisco Guerra and Cancan Huang.) 
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Inhibition assays were all carried out as described previously (18). 
2.6.9	  Transmission	  Electron	  Microscopy	  
(Note: this part was done by Francisco Guerra.) 
Specimen preparation. Aerobically purified and reconstituted AtIspG was diluted to 104.2 
µg/mL in its original buffer (100 mM HEPES, 200 mM KCl, pH 7.6) and negatively stained with 
2% uranyl formate (UF).  Ted Pella Ultrathin Carbon Type-A 400 mesh Cu grids were glow 
discharged for 70 sec in argon using a Denton DPG-1 Glow Discharge System.  All subsequent 
steps were performed immediately after glow discharging.  5 uL sample was applied to the grid, 
incubated at room temp for 60 sec, then blotted.  3 wash steps were performed by adding 5 uL 
wash buffer (10 mM HEPES, 100 mM KCl, pH 8) to the grid, waiting 60 sec, and blotting.  The 
grid was stained twice with 2% UF by adding 4.5 uL stain, waiting 3 min, then blotting.  After 
the final blot, the grid was allowed to air dry for > 10 min before inserting into the microscope.   
Imaging. All imaging was carried out using a Philips CM200 TEM operating at 120 keV 
that was equipped with a Peltier-cooled Tietz (TVIPS) 2k x 2k CCD camera.  All images were 
digitally recorded using TVIPS EMMENU 4.0 software.  The pixel sizes of different 
magnifications at 120 keV were calibrated using a Ted Pella beef liver catalase crystal 
calibration grid.  All images were recorded under low dose conditions, restricting the total dose 
per image to 12 e/Å2, or less.  Single-axis tilt-series were manually acquired at 88kX and 
150kX using 1-2.5 degree tilt increments over a tilt range of 0-50 degrees.  The models 
displayed here were recorded over a tilt range of 0-40 degrees at a 2.5 degree increment at 
150kX (pixel size of 0.93 Å/pixel).  
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Image Reconstruction.  Tomographic single particle reconstructions were compared, 
aligned, and combined to give the final model (27, 28).  Because of the missing wedge inherent 
in tomographic reconstructions involving single tilt series and a tilt series range of 0-40 degrees 
instead of +/-60 degrees, the final resolution of the reconstruction is anisotropic (29-31).  
However, the resolution in the plane of the grid (looking on the grid surface in the direction of 
the beam) combined with the flat orientation of the protein on the surface was sufficient to allow 
conclusions about a general molecular shape.   
The tilt series taken at 150kX were combined into MRC stacks using ImageJ (32).  
Preliminary tilt series alignment assessment was performed using TomoJ (ImageJ) (33).  The 
contrast transfer function (CTF) was estimated for each image in the tilt series using boxed out 
regions from each image using EMAN2 (28).  The furthest defocused (underfocused) image in 
the tilt series had a defocus of 690 nm corresponding to a CTF first zero at 15.1 Å.  The tilt 
series alignment was performed by, first, using fiducialess cross-correlation alignment with 
Etomo (IMOD); second, by manual correction with Midas (34) (IMOD).  Using an 
EMAN2/Sparx (28, 35, 36) python script we calculated the noise-compensated leave-one-out in 
2D (NLOO-2D) (29), then calculated NLOO-2D vs. tilt angle for each tilt series, and for the 
combined/aligned tilt series.  We also used EMAN2 to box out particles from an IMOD aligned 
tilt series (28, 34).  Two tomographic single particle reconstructions were normalized at a 
specified visualization threshold assuming a protein volume mass of 0.81 Da/Å3, and low pass 
filtered at 16 Å.  These 2 filtered reconstructions were then aligned in EMAN2 using a 
cross-correlation coefficient 3D alignment maximization algorithm that accounts for 
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tomographic missing wedge information.  Once the 3D → 2D alignment transforms were 
obtained for each tilt series (28, 35, 36), the 2 tilt series were combined and used to create the 
final model using the Central Slice Theorem or Projection Theorem (37) with a Fourier 
reconstruction method using a Gaussian kernel.  The FSCe/o (Fourier Shell Correlationeven/odd) 
(Figure  2.8J) and NLOO-2D (0.5 FRC (Fourier Ring Correlation) cut-off) vs. tilt angle 
resolution estimates for the combined/aligned tilt series (Figure 2.8K,L) were calculated for the 
final model (29).  These methods of resolution determination are similar to ones presented by 
Mastronarde (38) for dual-tilt tomography and for single particle electron tomography 
three-dimensional alignment (39).  The final reconstruction was created from all projections 
showing less than 30 Å on the NLOO-2D plot for the combined/aligned tilt series, Figure 2.8L, 
and low pass filtered at 20 Å, Figure 2.8J  (0.5 FSCe/o ~ 17.5 Å, (29)).  Manual rigid body 
fitting of the AtIspG homology model into the final AtIspG EM model and all 3D EM figures 
were performed with Chimera (40). The 2D images were prepared using EMAN2 (28). 
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2.7	  Figures	  and	  Tables	  
Figure 2.1  Schematic view of IspG structures. (A) Bacterial two-domain IspG domain 
arrangement. (B) Plant and malaria parasite IspG three-domain arrangement. (C) Crystal 
structure of Aquifex aeolicus IspG (3NOY) with the interfacial contact helices 7 of both A 
domains highlighted in red.  (D) ConSurf representation of AaIspG dimer.  A,B domains are 
circled. (E) Rosetta A-B domain docked AaIspG dimer structure.  (F) ConSurf representation 
of the closed AaIspG structure shown in E.  (G) One possible mechanism of interaction 
between two monomers of a three-domain IspG enzyme. (H) A hypothesized intra-molecular 
mechanism of action of a monomor of a three-domain IspG enzyme. 
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Figure 2.2  Oligomerization and catalysis of IspGs.  (A) Cross-linking experiment with 
oxidized TtIspG.  (B) Crossing-linking experiment with reduced TtIspG.  (C) Cross-linking 
experiment with lysozyme.  (D) Gel filtration chromatography and SDS-PAGE of TtIspG and 
AtIspG. Blue line: monomeric AtIspG; black line: reconstituted monomeric AtIspG; red line: 
dimeric TtIspG; green line: β-lactoglobulin; purple line: enolase; orange line: alcohol 
dehydrogenase; M: protein standard; 1: AtIspG; 2: TtIspG.  (E) Molecular weight estimation of 
TtIspG and AtIspG. Red triangle: dimeric TtIspG (~94 kDa); blue square: monomeric AtIspG 
(~74 kDa).  (F) Activity measurement of TtIspG mutants and chimera. a: wild type; b: 
E232A-(His)6; c: N346A-(His)6; d: C297S-(His)6; e: coexpression of E232A-(His)6 and 
N346A-(His)6 chimera; f: coexpression of E232A-(His)6 and C297S-(His)6 chimera; g: Duet 
expression of E232A-(His)6 and N346A-Strep tag chimera; h: Duet expression of E232A-(His)6 
and C297S-Strep tag chimera.  (G) Schematic of coexpressed/Duet TtIspG chimera.  (H) High 
resolution gel filtration chromatography of AtIspG. Blue line: monomer AtIspG; red line: 
aggregated AtIspG.  (I) Glutaraldehyde cross-linking experiment on AtIspG. 
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Figure 2.3 X-band EPR spectra of IspG with “X” or HMBPP. (A) TtIspG E232A N346A + 
MEcPP, 2 min incubation, with “X” being the major component in the EPR spectrum. (B) 
TtIspG E232A N346A + MEcPP, 1 hour incubation. Most of the “X” was converted to HMBPP. 
(C) AtIspG + MEcPP, 3 min incubation. This spectrum shows a mixture of “X” and the HMBPP 
product. (D) AtIspG + HMBPP. 
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Figure 2.4 ENDOR and HYSCORE spectra of the reaction intermediate X formed with AtIspG, 
EcIspG, and TtIspG chimeras. (A) 1H-ENDOR of AtIspG “X”. The Aiso=12 MHz proton signal is 
indicated. The inset is a Newman projection along C2-C2′, showing the dihedral angle-dependent 
hyperfine coupling constants of the three C2′ methyl protons. (B) HYSCORE spectrum of 
TtIspG E232A C297S chimera with [U-13C]-MEcPP. (C) As (B) but TtIspG E232A N346A 
chimera. (D) HYSCORE spectrum of AtIspG with [U-13C]-MEcPP. (E) HYSCORE spectrum of 
EcIspG + [1-17O]-labled “X”. All spectra were recorded at 9.7 GHz and 18K. (Courtesy of Dr. 
Weixue Wang) 
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Figure 2.5 HYSCORE and computational results for “X” reaction intermediate. (A) Correlation 
between computed hyperfine couplings (Aiso; Table S3) and experimental hyperfine couplings for 
H1(2), C2, H2′ (3), H3, H4(2), O1 and O3, based on experimental results in Ref. (2,16) and 
Figure 4E. The line is constrained through the origin and R=0.87, slope=1.55. The inset shows 
the model used for performing the calculation. (B) Spin density for the ferraoxetane model. One 
methyl proton (indicated by the arrow) has a very large (~12 MHz) coupling and originates from 
a trans (Fe-C2-C2′-H2′) hyperfine interaction. (Courtesy of Dr. Yong Zhang) 
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Figure 2.6 Homolog,y and EM models of AtIspG. (A) Homology model of the A. thaliana A* 
(insert) domain showing TIM barrel fold.  (B) Homology model of the A. thaliana catalytically 
active IspG monomer.  (C) ConSurf representation of AtIspG homology model (in the open 
form) showing low sequence homology in the A* domain.  (D) AtIspG homology model 
docked into a 20 Å AtIspG electron density map created by single particle electron tomography 
(Figure 2.12).  (E) Proposed evolutionary mechanism involving exon-loss and recombination 
that could explain how two domain catalytically active IspG dimers evolved into three domain 
catalytically active monomers. (Courtesy of Francisco Guerra) 
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Figure 2.7  ClustalW2 multiple sequence alignment for ten 3 domain IspG proteins.  The A* 
domain in A. thaliana IspG is defined as extending from K365-N635.  (At, AAO15446) 
Arabidopsis thaliana; (Gb, ABB78087) Ginkgo biloba; (Os, BAD19354) Oryza sativa; (Pp, 
EDQ68630) Physcomitrella patens; (Tp, XP_002292108) Thalassiosira pseudonana; (Ct, 
YP_002887686) Chlamydia trachomatis; (Li, AAS69566) Leptospira interrogans; (Bb, 
XP_001610211) Babesia bovis; (Pf, AAK12103) Plasmodium falciparum; (Ctep, AAM71395) 
Chlorobium tepidum. 
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Figure 2.7 Continued 
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Figure 2.7 Continued 
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Figure 2.8 Closed (Rosetta-docked) AaIspG structure docked with (A) MEcPP; (B) ferraoxetane 
“X”; (C) HMBPP (2); (D) BPH-1077 (7 in Figure 2.9) and their interactions with the TIM barrel 
and 4Fe4S cluster. 
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Figure 2.9 IspG inhibition.  IC50 values of a various putative inhibitors. Only the alkynes have 
good inhibitory activity.  
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Figure 2.10  X-band (9.7 GHz) HYSCORE spectrum of [U-13C] 6 bound to AtIspG. (Courtesy 
of Francisco Guerra and Dr. Weixue Wang) 
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Figure 2.11  Homology models of Arabidopsis thaliana A* (# 365-635, 
GeneBank:AAO15446.1) domain using (A) FUGUE (B) I-TASSER (C) LOMETS (D) FFAS (E) 
@TOME (F) ClustalW2 multi-sequence alignment with modeling by MODELLER using the A. 
aeolicus (PDB code 3NOY) monomer as a template. (Courtesy of Francisco Guerra) 
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Figure 2.12  The final AtIspG tomographic single particle reconstruction produced from 2 
three-dimensionally aligned low dose tilt series of AtIspG particles negatively stained with 2% 
uranyl formate.  Two rotated orientations of the final model are depicted.  (A) Orientation 1 of 
AtIspG homology model.  (B) Schematic of AA*B connectivity and positioning for orientation 
1.  (C) Schematic of orientation 2.  (D) Rotated orientation 2 of AtIspG homology model.  (E, 
F) Rigid body fit of AtIspG homology model into electron density map created from single 
particle electron tomography.  Shown in orientations 1 and 2, respectively.  (G, H) Electron 
density map created from single particle electron tomography.  Shown in orientations 1 and 2, 
respectively.  (I) Sample projections from the input tilt series image stack.  Shown are 
representative Euler angles, the original projection from the tilt series, the projection low pass 
filtered to 20 Å, a reprojection from a tomographic reconstruction from 1 tilt series, and a 
reprojection from the combined/aligned tilt series single particle reconstruction.  (J) Fourier 
Shell Correlation even/odd (FSCe/o)  resolution curve for the reconstruction of a single particle 
from 2 combined/aligned tilt series.  0.5 FSCe/o = 17.5 Å.  (K) Noise-compensated 
leave-one-out in 2D (NLOO-2D) vs tilt angle resolution estimate for 2 single particle tilt series.  
Resolution assessed at 0.5 FRC.  (L) NLOO-2D for the final combined/aligned tilt series 
displayed according to each input tilt series.  Resolution assessed at 0.5 FRC. (Courtesy of 
Francisco Guerra) 
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Figure 2.12 Continued 
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Figure 2.12 Continued 
  
 
87 
 
Table 2.1 SCORECONS results for T. thermophilus and A. aeolicus IspGs, together with mutant 
activities. 
Ranking Amino 
Acid 
Mutant Relative 
activity 
of 
TtGcpE 
mutant 
Residue 
number in 
TtGcpE 
Scorecons 
score of 
TtGcpE 
Residue 
number 
in 
AaGcpE 
Scorecons 
score of 
AaGcpE 
Reported 
Activity 
1 E E232A 0.63% 232 0.995 204 0.994 <0.094%(E
204Q) 
2 S S202A 17.00% 202 0.993 174 0.997   
3 N N346A 0.75% 346 0.99 303 0.905   
4 R R302A 3.86% 302 0.985 270 0.899   
5 S S262A 20.77% 262 0.98 234 0.952   
6 N N112A 11.20% 112 0.978 103 0.978 0.5% 
(N103D) 
7 E     274 0.975 242 0.986 8% 
(E242Q) 
8 H H227A 3.93% 227 0.97 199 0.95   
9 N     145 0.956 132 0.978 no gene 
expression 
10 R     260 0.946 232 0.936   
11 R R141A 4.43% 141 0.942 128 0.961 <0.034%(R
128K) 
12 S     148 0.938 135 0.978   
13 T T231A 7.76% 231 0.933 203 0.966   
14 E     350 0.931 307 0.908   
15 M     29 0.929 28 0.955   
16 T     258 0.926 230 0.927   
17 K K204A 4.80% 204 0.924 176 0.938   
18 L     282 0.921 250 0.857   
19 R R56A 5.10% 56 0.916 55 0.947 <0.043% 
(R55K) 
20 R     110 0.914 101 0.961 0.2%(R101
K) 
21 Q     27 0.909 26 0.924   
22 D D87A 2.47% 87 0.904 81 0.919 <0.029% 
(D81N) 
23 I     255 0.901 227 0.885   
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24 D     257 0.899 229 0.93   
25 L     251 0.887 223 0.922   
26 S     243 0.884 215 0.882   
27 H H89A 13.70% 89 0.879 83 0.866   
28 A     182 0.877 156 0.843   
29 S     28 0.874 27 0.852   
30 T     115 0.872 106 0.868 
38% 
(N106D) 
111 E E53A 60% 53 0.645 52 0.672   
235 T T303A 100% 303 0.304 - -   
            26 0.924 
0.9%(Q26E
) 
            256 0.675 
48% 
(R256K) 
            307 0.908 
28% 
(E307D) 
            270 0.86 
<0.0014% 
(C270S) 
            273 0.874 
<0.0014% 
(C273S) 
            306 0.91 
<0.0014% 
(C306S) 
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Table 2.2 Calculated Aiso for the ferraoxetane reaction intermediate model and Aiso or A 
determined by ENDOR/HYSCORE experiments (Aiso was obtained from spectral simulations of 
orientation-selective data, and; A was estimated from the ENDOR/HYSCORE spectra taken at 
g2). (Courtesy of Dr. Yong Zhang) 
 
calculated Aiso 
(MHz) 
experimental 
Aiso or A (MHz) 
C1H1 0.6 A  = 3.2 
C1H2 0.3 A = 3.2 
C2 38.9 Aiso = 17.7 
C2'H1 9.1 Aiso = 11.3 
C2'H2 2.0 A = 3.7 
C2'H3 1.1 A = 1.3 
C3 0.3 Aiso = 3 
C3H 3.6 A = 3.2 
C4H1 0.3 A = 3.2 
C4H2 0.2 A = 2.0 
O1 0.68 A = 0.15 
O3 11.4 A = 9 
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Chapter 3: Benzoic Acids as Anti-malarial Drug Agents: A 
Crystallographic Investigation 
3.1	  Acknowledgements	  and	  Other	  Contributions	  
Dr. Yonghui Zhang, Dr. Ke Wang, Dr. Kai Li and Yang Wang synthesized compounds and 
Wei Zhu performed inhibition assay. PvGGPPS expression system was provided by Dr. 
Raymond Hui. Use of the Advanced Photon Source was supported by the US Department of 
Energy, Office of Science, Office of Basic Energy Sciences, under Contract 
DE-AC02-06CH11357. Use of the Life Science Collaborative Access Team Sector 21 was 
supported by the Michigan Economic Development Corporation and the Michigan Technology 
Tri-Corridor for the support of this research program (Grant 085P1000817). 
3.2	  Introduction	  
Many drugs target isoprenoid biosynthesis [1].  For example, the most widely prescribed 
drug, the statin Lipitor, blocks cholesterol biosynthesis at the level of HMG-CoA reductase[2]; 
bisphosphonate drugs such as risedronate (20, Scheme 1.7) and zoledronate (19, Zometa, 
Scheme 1.7), used to treat bone resorption diseases, inhibit farnesyl diphosphate (21, FPP, 
Scheme 1.8) synthase [3], and azoles such as miconazole and posaconazole [4] inhibit lanosterol 
14α-demethylase, blocking ergosterol biosynthesis in yeasts and fungi. There is, therefore, 
considerable interest in the discovery and development of novel isoprenoid biosynthesis 
inhibitors as anti-infectives, not least because of the rapid increase in resistance in bacteria and 
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protozoa to current drugs, e.g. with Staphylococcus aureus resistance to methicillin [5] (MRSA) 
and the discovery of resistance to artemisinin (18, Scheme 1.6) [6] in Plasmodium falciparum, 
the causative agent of the most serious form of malaria, being of major public health concern.   
Here, we describe recent work aimed at developing new leads against malaria in which we 
target one unique enzyme: geranylgeranyl diphosphate synthase (GGPPS [7]) from Plasmodium 
vivax. In Plasmodium spp., the enzyme GGPPS catalyzes the trans head-to-tail condensation of 
IPP with dimethylallyl diphosphate (DMAPP) to produce geranyl, farnesyl and finally 
geranylgeranyl diphosphate, used in protein prenylation and carotenoid biosynthesis [8] inside 
Plasmodium-infected red blood cells, as well as in menaquinone-4 biosynthesis (Figure 3.1). The 
bisphosphonate class of drugs, e.g. risedronate (20, Scheme 1.7), inhibit GGPPS (from P. vivax), 
[9] and bisphosphonates have been shown to kill malaria parasites both in vitro [10-13] and in 
vivo [11,12]. However, the bisphosphonate class of drugs bind very tightly to bone mineral [14] 
– a desirable feature for a bone drug, but not an anti-infective, since these drugs are rapidly 
removed from the circulation. There has been considerable interest in developing 
non-bisphosphonate prenyltransferase inhibitors that are less hydrophobic and do not bind to 
bone. For example, Jahnke et al. recently reported a series of farnesyl diphosphate synthase 
(FPPS) inhibitors, dicarboxylic acids, that bound to a novel, allosteric site [15]. Observations 
have been made with GGPPS [16] or FPPS [17] inhibitors in which incorporation of a cationic 
feature actually increases activity. It thus seemed likely that carboxylic acids with an addition to 
a carbocation feature might represent new leads for GGPPS inhibition. Here, we report progress 
in the development of benzoic acids as new chemo-type non-bisphosphonate GGPPS inhibitors, 
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as well as their binding modes which targets into GGPP site. 
According to the existing structural information of PvGGPPS in complex with various 
substrates or inhibitors [7,18], we can take advantage of such information and apply the 
structure-based drug/lead optimization method to improve the efficacy of this class of small 
molecules. 
3.3	  Results	  and	  Discussion	  
In earlier work [16,19] we and others found that – there were up to four binding sites for 
substrates (IPP, FPP); product (GGPP) and bisphosphonate inhibitors, in P. vivax, human and 
yeast GGPPS. The a site (Figure 3.2A) is the Mg2+/conserved Asp site that binds the PPi moiety 
of FPP in yeast GGPPS and the PPi in GGPP in the yeast and human enzymes, in addition to 
binding to the bisphosphonate groups in many inhibitors [16,19]. The b site is a hydrophobic site 
that binds the FPP (yeast) and GGPP (P. vivax) side-chains [7,16]. The c site is Lys/Arg rich and 
can bind the IPP diphosphate or the GGPP diphosphate, in P. vivax GGPPS [7]. Site d binds the 
GGPP hydrophobic side-chain in yeast and human GGPPS. In principle, then, the hydrophobic 
carboxylic acids could bind into ab, ad, bc or cd. 
Since Plasmodium GGPPS has been identified as a potent drug target in treating malaria, we 
 
Scheme 3.1 First generation of PvGGPPS inhibitors. 
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are eager to discover more potent small molecules against Plasmodium GGPPS. The first 
compound, BPH-981 (1, Scheme 3.1), is only a simple version of benzoic acid with a long acyl 
chain (C14). Surprisingly, even though it has no activity but the electron density map of 
BPH-981 shows its head group binds to the GGPP site instead of FPP site like we expected 
(Figure 3.3A), in site bc. The discontinuity of density map indicates it lacks of a good binding 
and inhibiting ability against PvGGPPS as we tested, but the head group clearly shows it binds to 
the IPP site. In IPP site, there are couple positive charged residues that assist binding of small 
molecules: Lys-81, Arg-84, Arg-135 and Arg-136 (Figures 3.3A,3.4A). Those residues might 
play pivotal roles in electrostatic interactions. In addition, some residues, such as Gln-119 and 
Tyr-247 along with a long hydrophobic cavity could also increase binding efficiency. In 
BPH-981/PvGGPPS complex structure, Arg-84 binds to the carboxylate group in a distance of 
2.8Å and the long acyl chain occupied the hydrophobic cavity (Figure 3.3A). The non-linear 
binding pose at the C6~C8 of acyl chain might contribute to flexibility of the compound, and 
hence reduce the inhibition as well as the occupancy in the crystal structure. Remarkably, it is the 
first time we discover a new class of compounds that bind to GGPP/IPP site instead of FPP site 
as we generally found across all bisphosphonates [7,18]. Several generations of compounds has 
been made and tested against PvGGPPS (Figure 3.5). Those compounds show promising 
increase of activity with replacing to different moieties from inactive to 14 µM. Full 
crystallographic data collection and structure refinement statistics are shown in Table 3.1 and 
electron density maps are presented in (Figure 3.3). 
One of the second generation of compounds, BPH-1115 (2, Scheme 3.1) has increased its 
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IC50 to 800 µM (Scheme 3.1). BPH-1115/PvGGPPS complex structure shows the benzoic acid 
group still resides in IPP site as we expected from BPH-981 (Figure 3.3B). Arg-84 binds to the 
carboxylate group in a distance of 2.6Å and Asp-287 forms a weak hydrogen bond with the 
oxygen atom in 3.6Å. Mechanistically, it is known that the cationic feature enhances the 
inhibition against FPPS [17], due to the required formation of carbocationic species during the 
sequential ionization-condensation-elimination mechanism in trans-prenyltransferases [20,21]. 
However, the nitrogen atom in our complex structure is not close to the cationic nitrogen atom of 
the zoledronate (Figure 3.6), and it doesn’t have any significant interactions in the crystal 
structure, or has any enzymatic inhibition (IC50>800µM, Scheme 3.1, Figures 3.3B,3.4B). On the 
other hand, the acyl chain shows a “bent” configuration where the middle part of acyl chain 
crossover to the FPP site, which indicates that the molecule might be too long for binding 
(Figure 3.6). In addition, the low occupancy of compound indicates that it might have high 
flexibility and multiple binding poses, which cannot be resolved in crystal structure. This might 
then refer to the lack of tight binding to the enzyme. 
From the third generation of compounds, we screened ~200 benzoic acid derivatives against 
an expressed P. vivax GGPPS crystal structure was recently reported [7]:  structures and IC50 
values (with FPP and IPP as substrates) are shown in (Figure 3.5). The top most active 
compounds were nitro- or bromo-carboxylates having IC50 values in the range 14-31 µM.  
Under the same reaction conditions, the IC50 values for some of the most potent bisphosphonate 
PvGGPPS inhibitors, risedronate (20, Scheme 1.7) and zoledronate (19, Scheme 1.7), are both 
~0.5 µM. However, these bisphosphonates have little activity in vitro against malaria parasites 
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and no activity in vivo [10-13].  
We obtained the crystal structures of four compounds shown in Figure 3.5 which have a 
variety of structural motifs, and activities. As can be seen in (Figures 3.3C-F), in each of the four 
structures (BPH-1158 (3), BPH-1182 (4), BPH-1186 (5), BPH-1251 (6); Figure 3.5), the bound 
ligand occupies the GGPP binding site seen in the previously discovered BPH-981 (1)/PvGGPPS 
and BPH-1115 (2)/PvGGPPS complex structures, that is, site bc (Figure 3.2B). In BPH-1158 
(3)/PvGGPPS structure, the bulky sulfonamide group occupies the IPP site and moves the 
benzoic acid group away from the core. Tyr-247 forms a H-bond to the carboxylate group in a 
distance of 2.8Å to stabilize the molecule. Although it has fewer interactions, the tail with a rigid 
and shorter chain length makes it fits into the hydrophobic pocket, and therefore, makes the 
compound more active (IC50=94 µM) and shows a well-defined density map (Figure 3.3C). As 
expected based on the adoption of the GGPP/PvGGPPS binding mode, the CO2- groups in 
BPH-1186 (5) and BPH-1251 (6, Figure 3.5) interact via electrostatic interactions, with Lys-301 
and Arg-135 (Figures 3.3E,F and 3.4E,F).  In addition, Arg-135 interacts with the phenyl group 
in the side-chain via a cation-π interaction, as does Lys-81 with the benzoate phenyl ring.  
Arg-136 interacts via H-bonding with the NO2 and SO2 groups, and Lys-81 has a similar 
interaction with the NO2 group, in BPH-1186.  The rapid decrease in activity correlates with 
fewer interactions with these key residues in the BPH-1182 structure (Figures 3.3D,3.4D), and 
the lack of electrostatic interactions with the CO2- in the BPH-1158 structure. We attribute the 
lack of activity of BPH-981 to the fact that it contains a salicylate group, which could decrease 
intermolecular interactions with the protein, and in the case of BPH-1115, the lack of an 
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electron-withdrawing substituent (to decrease the CO2H pKa value) will reduce any strong 
Coulombic interactions with Arg/Lys residues, while the cationic side-chain is likely simply 
repulsive, being located in a hydrophobic channel.  These results clearly show then that an 
electron-withdrawing group improves enzyme inhibition activity, presumably because this 
feature can facilitate a Coulombic or electrostatic interaction between the benzoic acid CO2- 
group and protein Lys/Arg residues, rather than simply a hydrogen bond interaction. 
 Pharmacophore features of these 35 benzoic acid inhibitors give us a general view of what 
are the essential characteristics should be equipped (Figure 3.7). All the 35 compounds were 
aligned in MOE and the consensus pharmacophore features were subsequently derived [22]. As 
can be seen, BPH-1186 and BPH-1251, the most active compounds within six crystal structures, 
share all common features. First, they require an electron-withdrawing group on the head group 
region, such as nitro or sulfonamide groups. Second, carboxylate group is extremely essential for 
controlling the position of head group, providing an electrostatic-favored region for protein 
binding. Third, a long acyl chain which binds into hydrophobic cavity in PvGGPPS. Unlike these 
two most active molecules, BPH-1182 lacks an electro-withdrawing substituent and BPH-1158 
has a bulky morpholine group hindering the ligand binding. 
 In addition, we further test if our enzymatic data would fit into a validated model which 
might assist us to improve developing more potent compounds. First, chemical structures of 22 
inhibitors plus 7 inactive compounds (IC50 > 3 mM) with measured IC50 values were washed, 
protonated, energy minimized and aligned in MOE [22]. The aligned structures with IC50 values 
were then imported into sybyl-X program [23] to build the Molecular Similarity Indices in a 
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Comparative Analysis (CoMSIA) model [24]. All the results are shown in Table 3.2 and related 
statistics are shown in Table 3.3. The CoMSIA investigation showed a good correlation between 
predicted pIC50 and experimental pIC50 with a R2 of 0.99 within the training set (Figure 3.8). The 
test sets were subsequently performed to leave two molecules out each time and predict their 
pIC50 values by using the new set of partial-least-squares (PLS) regression analysis results. The 
q2 values were between 0.699 and 0.779 and the R2 values were between 0.966 and 0.994. Most 
of compounds had minimal errors within 0.01-0.97 with a RMS of 0.306 which indicates the 
model was correctly validated. Correlation between experimental pIC50 and predicted pIC50 
shows a R2 of 0.57. In addition, we also predicted some of the active and inactive compounds to 
verify the goodness of the model (Table 3.2). 11 actives and 1 inactive were subjected to align 
with the existing previously aligned structures. The predicted pIC50 values were predicted by 
using the previous generated PLS analysis results. The average results from 11 test sets plus the 
training set showed an error between 0.17 and 2.05. 10 out of 12 compounds were correctly 
predicted based on this analysis (Table 3.2). Therefore, it suggested that those values were 
mostly correctly predicted by the current QSAR model. Graphic representation of QSAR results 
with the BPH-1251 (6, Figure 3.5) shown in Figure 3.9A-D. The head group region contributed 
to a strong favorite in electrostatic interaction (Figure 3.9A). In the tail region, the acyl chain is 
superimposed with hydrophobic favorable pocket (Figure 3.9B) and the steric hindrance might 
indicate the size of molecule should not be too bulky. The longer chain length of the molecule 
might not be beneficial for inhibition (Figure 3.9C). It is also strongly suggested that the ring 
regions play roles as hydrogen bond donors (Figure 3.9D) or acceptor. In summary, the CoMSIA 
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QSAR study gave us a glance of how well the current model could provide us a guideline of 
developing more potent or selective inhibitors. 
3.4	  Conclusions	  
 We tested a series of lipophilic benzoates as inhibitors of a Plasmodium GGPPS.  The 
most active compound had an IC50 = 14 µM (Ki = 1.2 µM).  We further solved the structures of 
six compounds bound to PvGGPPS, finding that in all cases, the ligands occupied solely the 
GGPP product site seen in the PvGGPPS x-ray structure, not the alternative binding sites found 
with bisphosphonate inhibitors. The pharmacophore features and QSAR studies suggest the 
importance of the carboxylate head group and the length of hydrophobic tail determined the 
activity of the compounds. With PvGGPPS inhibitors, an electron-withdrawing substituent was 
essential for activity, and incorporation of cationic features in the side-chain (necessary for 
activity with the prenyl transferase FPPS) abrogated inhibition.  These results are also of 
interest since carboxylic acids lack the features needed for bone-binding, making them more 
amenable for development as anti-malarial leads. 
3.5	  Materials	  and	  Methods	  
3.5.1	  Expression	  and	  Purification	  of	  PvGGPPS	  
A clone encoding Plasmodium vivax GGPPS (PlasmoDB gene ID code Pv092040) with an 
N- terminally His6-tagged fusion protein and a tobacco etch virus protease site was expressed in 
Escherichia coli BL21-codon Plus (DE3) RIL (Stratagene) at 15 °C in baffled flasks. Cells were 
lysed by sonication in the presence of Benzonase Nuclease (Novagen) and a protease inhibitor 
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cocktail (Sigma), and the protein then purified chromatographically by using a 
Ni-nitrilotriacetate acid (Ni-NTA) resin. EDTA was added immediately to the elution fraction to 
1 mM and 5 mM DTT added after 15 min. The eluted protein was then concentrated and loaded 
onto a Sephadex S-200 gel filtration column and fractions containing PvGGPPS collected for 
further experiments. 
3.5.2	  Inhibition	  Assay	  of	  PvGGPPS	  
The P. vivax GGPPS inhibition assays were carried out by using 96-well plates with 150 µL 
of reaction mixture in each well. The condensation of geranyl diphosphate (GPP) with 
isopentenyl diphosphate (IPP) was monitored at room temperature by using a continuous 
spectrophotometric assay for phosphate releasing enzymes in a reaction mixture containing 25 
mM HEPES and 2.5 mM MgCl2 at pH 7.4. The inhibitors were preincubated with the enzyme 
for 30 min at room temperature. The IC50 values were obtained from fitting the dose-response 
curve using Prism 4.0.22 [25]. 
3.5.3	  Crystallization	  of	  PvGGPPS	  
Wild-type PvGGPPS was eluted from the Sephadex S-200 column using 500 mM NaCl, 10 
mM Hepes, pH 7.5, and concentrated to 15 mg/mL. Cocrystallization of P. vivax geranylgeranyl 
diphosphate synthase (PvGGPPS) with the benzoic acid inhibitors was carried out by first 
incubating PvGGPPS with 1 mM inhibitors (Inhibitors were dissolved in DMSO as 20mM stock 
solution.) for 30 min, on ice. After incubation, 1.5 µL of crystallization buffer (19% PEG 3350, 1 
mM MgCl2, 0.1 M Tris•HCl pH 7.4, and 0.1 M LiSO4) was added to 1.5 µL of incubated protein 
by using the hanging-drop method, at 15°C. Crystals appeared the next day. Crystals need to be 
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mounted within a week otherwise the quality of crystals will decay dramatically. Data collection 
was carried out at the Life Sciences Collaborative Access Team and indexed, integrated, and 
scaled by using the HKL2000 program package [26]. Structures were determined by using the 
molecular replacement method using the Phaser program in CCP4 suite [27]. The PvGGPPS 
structure [Protein Data Bank (PDB) ID code 2Q58], minus the ligand, was used as a template. 
Further model building and refinement employed Coot [28], Refmac in CCP4 suite [27], and the 
ProDRG server [29]. Figures were obtained by using PyMOL [30]. 
3.5.4	  Pharmacophore	  Search	   	  
Pharmacophore search was done by using MOE [22]. All the structures of ligands were 
imported in MOE database along with pIC50 and compound ID. After import, all the structures 
were subject to wash, assign the partial charges and perform energy minimization, individually. 
Molecules with correct assignment were later import into MOE molecule screen and perform the 
flexible alignment. All the aligned structures were subsequently followed by pharmacophore 
query. The high percentage of consensus pharmacophore features were selected and plotted as 
Figure 3.7. 
3.5.5	  Quantitative	  Structure–Activity	  Relationship	  (QSAR)	  Investigation	  
Selected 11 inhibitors associated with correctly measured IC50 from Figure 3.5 plus 7 inactive 
compounds were optimized, energy minimized and flexibly aligned in MOE. The aligned 
structures were imported into sybyl 8.0 for model construction. The cross-validation method in 
partial-least-squares (PLS) analysis was first checked to obtain q2 and optimal number of 
component. The optimal number of component was added into no validation method in PLS 
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analysis. The results of calculated electrostatic, steric, hydrophobic, donor and acceptor values 
were shown in the spreadsheet. In order to validate the model, two compounds were leave out 
during the test set and 11 test set were generated. After determining all the required fields, the 
calculated pIC50 values were predicted by using the PLS analysis results. In addition, 11 active 
with pre-determined IC50 values plus 1 inactive were subjected to further validation by using the 
obtained PLS analysis results from training and test sets.   
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3.6	  Figures	  and	  Tables	  
Figure 3.1 Schematic illustration of reaction mechanisms for PvGGPPS. GGPPS, sequential 
ionization and condensation mechanism, characteristic of trans-prenyltransferases, formation of 
menaquinone, carotenoids and protein prenylation.  
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Figure 3.2 Geranylgeranyl diphosphate synthase structures and interactions. (A) The 4 ligand 
binding domains in GGPPS. a = Mg2+/bisphosphonate/DMAPP/FPP diphosphate domain. b = 
FPP, GGPP hydrophobic sidechain-binding site. c = IPP/bisphosphonate polar domain. d = 
GGPP, BPH-629 hydrophobic sidechain pocket. (B) Superposition of the 4 benzoic acid x-ray 
structures. All bind to the bc site seen with GGPP bound to PvGGPPS. 
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Figure 3.3 Electron density of six benzoic acid inhibitors in complex with PvGGPPS shown in 
local interactions. (A) BPH-981. (B) BPH-1115. (C) BPH-1158. (D) BPH-1182. (E) BPH-1186. 
(F) BPH-1251. 
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Figure 3.4 Ligplot representation of six PvGGPPS/ligands complex structures. (A) BPH-981. (B) 
BPH-1115. (C) BPH-1158. (D) BPH-1182. (E) BPH-1186. (F) BPH-1251. 
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Figure 3.5 Chemical structures of PvGGPPS inhibitors. IC50 values of PvGGPPS against various 
benzoic acid derivatives. Numbers in blue refer to the crystal structure of these compounds in 
complex with PvGGPPS have been determined. 
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Figure 3.6 Superposition of zoledronate and BPH-1115 in PvGGPPS. It shows a bent 
configuration which overlap with ZOL structure (shown in the pink dashed circle). 
 
  
113 
 
Figure 3.7 Pharmacophore features of active benzoic acid derivatives. The common features of 
listed compounds from Figure 3.5 were generated by using MOE [22]. Each mashed sphere 
represents for individual common feature. Yellow: electron withdrawing/anionic donor or 
acceptor; Red: anionic acceptor or donor; Orange: aromatic rings; Grey: hydrophobic chain. (A) 
BPH-1158. (B) BPH-1182. (C) BPH-1186. (D) BPH-1251. 
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Figure 3.8 Graphical comparison between experimental and predicted pIC50 values for 
PvGGPPS inhibition: CoMASIA training set () and test set predictions (☐). For the training 
set only, R2=0.99; for the test set, R2=0.57. 
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Figure 3.9 Graphical representation of the CoMASIA fileds superimposed on the most active 
compound (6, BPH-1251) in the training set. (A) electrostatic favorable (blue) and unfavorable 
(red); (B) hydrophobic favorable (yellow) and unfavorable (white); (C) steric favorable (green) 
and unfavorable (purple); (D) donor favorable (orange) and unfavorable (magenta). 
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Table 3.1 Data collection and refinement statistics. 
	   PvGGPPS/1 PvGGPPS/2 PvGGPPS/3 PvGGPPS/4 PvGGPPS/5 PvGGPPS/6 
Crystals (3SFL) (3P1K) (3SFN) (3SFO) (3SFQ) (3SFR) 
Data collection 
Space group  P212121 P212121 P212121 P21 P212121 P212121 
Unit cell dimension (Å) 	   	   	   	   	   	  
a, b, c (Å) 
107.25, 
108.31, 
140.74 
107.45, 
108.59, 
140.32 
107.78, 
108.38, 
140.04 
84.07, 
117.22, 
92.79 
106.92, 
108.29, 
139.87 
107.45, 
108.62, 
140.67 
X-ray source APS 21-ID-F APS 21-ID-F APS 21-ID-F APS 21-ID-F APS 21-ID-F APS 21-ID-F 
Wavelength (Å) 0.9787 0.9787 0.9787 0.9787 0.9787 0.9787 
Resolution (Å) 
50-2.50 
(2.54-2.50)  
50-2.89 
(2.94-2.89)  
50-2.15 
(2.19-2.15) 
50-2.70 
(2.75-2.70) 
50-2.10 
(2.14-2.10) 
50-2.70 
(2.75-2.70) 
No. of reflection observed  418,040 229,594 865,103 231,318 689,414 442,309 
Unique 
58,468 
(2,892) 
35,900 
(1,735) 
170,179 
(8,233) 
43,920 
(2,117) 
91,912 
(4,507) 
46,114 
(2,257) 
Completeness (%)  99.9 (100.0) 95.9 (94.2) 97.3 (94.3) 99.5 (97.5) 99.8 (99.5) 100.0 (99.9) 
R-merge  0.110 (0.436) 0.128 (0.501) 0.126 (0.600) 0.126 (0.561) 0.094 (0.581) 0.193 (0.777) 
I/σI 36.2 15.9 17.5 18.3 26.4 11.16 
Multiplicity 7.1 (6.2) 6.4 (5.2) 5.1 (3.9) 5.3 (3.9) 7.5 (5.4) 9.6 (5.1) 
Refinement statistics  
Resolution range (Å)   50-2.50 50-2.89 40-2.15 30-2.7 50-2.10 40-2.70 
R-work/R-free (%) 19.5/25.3 24.7/28.2 19.8/24.9 25.9/29.6 17.7/24.9 20.0/27.6 
RMSD 	   	   	   	   	   	  
Bond lengths  0.008 0.014 0.006 0.013 0.01 0.015 
Bond angles  1.119 1.933 0.953 1.407 0.882 1.58 
No. of atoms 	   	   	   	   	   	  
Protein 2,864 2,801 2,796 2,624 2,784 2,817 
B average (Å2) of protein 35.83 35.46 25.18 46.81 29.58 16.6 
Ligand 25 25 35 27 31 33 
B average (Å2) of ligand 71.77 78.09 49.86 53.68 52.13 70.17 
*Values in parentheses correspond to the highest resolution shell. 
  
117 
 
Table 3.2 Experimental (IC50 and pIC50) and predicted CoMSIA (pIC50) results for benzoic acid 
analogs inhibition of PvGGPPS. Corresponded chemical structures can be found in Figure 3.5. 
a Bold values represent predicted activities of compounds that were not included in the training 
set. b Average predicted value.  
	   	   	  
CoMSIA	  predicted	  pIC50	  (M)	  
	  
experimental	  activity	  
	  
test	  sets	  a	  
	   	  
ID	   IC50	  (μM)	   pIC50	  (M)	  
pIC50	   	  
(training	  set)	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   pred	   error	  
1058	   138.75	   3.86	   3.82	   3.84	   3.78	   3.87	   3.82	   3.82	   3.80	   3.79	   3.82	   3.83	   3.82	   3.79	   3.84	   0.01	  
1064	   258.7	   3.59	   3.64	   3.22	   3.26	   3.60	   3.62	   3.65	   3.63	   3.50	   3.64	   3.63	   3.65	   3.67	   3.26	   0.33	  
1066	   104	   3.98	   3.92	   3.97	   3.94	   3.99	   3.92	   3.95	   3.95	   3.95	   3.91	   3.95	   3.91	   3.94	   3.92	   0.06	  
1115	   800	   3.10	   3.07	   3.15	   3.05	   3.10	   3.06	   3.05	   3.06	   3.15	   3.08	   3.06	   3.11	   3.06	   3.15	   -­‐0.05	  
1148	   122	   3.91	   3.95	   3.99	   3.99	   3.95	   3.94	   3.98	   4.15	   3.99	   3.95	   3.92	   3.94	   3.95	   4.15	   -­‐0.24	  
1152	   186.6	   3.73	   3.73	   3.48	   3.74	   2.76	   3.76	   3.72	   3.74	   3.59	   3.75	   3.72	   3.73	   3.70	   2.76	   0.97	  
1153	   142.82	   3.85	   3.84	   3.84	   3.89	   3.82	   3.83	   3.83	   3.87	   3.78	   3.85	   3.83	   3.84	   3.98	   3.98	   -­‐0.14	  
1158	   94.5	   4.02	   4.05	   4.06	   4.08	   4.01	   4.03	   4.32	   4.05	   4.01	   4.05	   4.05	   4.03	   4.02	   4.32	   -­‐0.29	  
1182	   62.46	   4.20	   4.14	   4.14	   4.17	   4.18	   4.15	   4.14	   4.18	   4.25	   4.14	   4.14	   4.16	   4.12	   4.25	   -­‐0.05	  
1249	   29.99	   4.52	   4.54	   4.59	   4.58	   4.57	   4.54	   4.52	   4.55	   4.51	   4.75	   4.54	   4.57	   4.52	   4.75	   -­‐0.23	  
1250	   31.25	   4.51	   4.54	   4.50	   4.48	   4.52	   4.54	   4.51	   4.51	   4.50	   4.54	   4.53	   4.54	   4.53	   4.48	   0.02	  
1251	   31.25	   4.51	   4.47	   3.92	   4.44	   4.47	   4.47	   4.48	   4.47	   4.55	   4.53	   4.47	   4.46	   4.48	   3.92	   0.58	  
1262	   68.54	   4.16	   4.34	   4.36	   4.33	   4.31	   4.34	   4.32	   4.33	   4.37	   4.33	   4.38	   4.33	   4.35	   4.38	   -­‐0.22	  
1263	   41.76	   4.38	   4.35	   4.34	   4.34	   4.27	   4.35	   4.32	   4.37	   4.38	   4.33	   4.38	   4.35	   4.36	   4.27	   0.11	  
1441	   122.2	   3.91	   3.88	   3.90	   3.93	   3.89	   3.89	   3.90	   3.88	   3.89	   4.14	   3.89	   3.88	   3.88	   4.14	   -­‐0.22	  
1456	   142.15	   3.85	   3.86	   3.90	   3.81	   3.92	   3.89	   3.88	   3.87	   3.91	   3.85	   3.88	   3.87	   4.19	   4.19	   -­‐0.34	  
1462	   32.37	   4.49	   4.42	   4.40	   4.42	   4.36	   4.43	   4.42	   4.46	   4.44	   4.43	   4.37	   4.33	   4.42	   4.33	   0.16	  
1463	   24.37	   4.61	   4.49	   4.45	   4.50	   4.44	   4.48	   4.48	   4.53	   4.50	   4.49	   4.41	   4.43	   4.50	   4.41	   0.21	  
1468	   34.66	   4.46	   4.40	   4.40	   4.39	   4.36	   4.40	   4.36	   4.39	   4.42	   4.38	   4.42	   4.39	   4.41	   4.36	   0.10	  
1481	   28.25	   4.55	   4.59	   4.59	   4.59	   4.63	   4.18	   4.60	   4.61	   4.60	   4.57	   4.62	   4.60	   4.58	   4.18	   0.37	  
1484	   72.34	   4.14	   4.15	   4.18	   4.10	   4.10	   4.16	   4.17	   4.14	   4.01	   4.14	   4.15	   4.17	   4.18	   4.17	   -­‐0.03	  
1485	   50.88	   4.29	   4.39	   4.40	   4.39	   4.39	   4.38	   4.37	   4.38	   4.41	   4.38	   4.39	   4.37	   4.41	   4.38	   -­‐0.09	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  981	   >3000	   2.52	   2.39	   2.43	   2.43	   2.39	   2.39	   2.39	   2.41	   2.40	   2.40	   2.39	   2.40	   2.44	  
	   	  1299	   >3000	   2.52	   2.60	   2.76	   2.55	   2.58	   2.58	   2.59	   2.57	   2.70	   2.58	   2.62	   2.59	   2.58	  
	   	  1432	   >3000	   2.52	   2.60	   2.88	   2.60	   2.56	   2.60	   2.58	   2.60	   2.66	   2.59	   2.60	   2.61	   2.59	  
	   	  1433	   >3000	   2.52	   2.55	   2.49	   2.57	   2.57	   2.56	   2.52	   2.55	   2.48	   2.56	   2.56	   2.54	   2.52	  
	   	  1452	   >3000	   2.52	   2.48	   2.41	   2.50	   2.48	   2.48	   2.56	   2.47	   2.65	   2.46	   2.49	   2.47	   2.54	  
	   	  1461	   >3000	   2.52	   2.66	   2.68	   2.64	   2.69	   2.65	   2.66	   2.66	   2.67	   2.67	   2.64	   2.64	   2.64	  
	   	  1464	   >3000	   2.52	   2.44	   2.45	   2.44	   2.42	   2.44	   2.42	   2.44	   2.34	   2.45	   2.44	   2.44	   2.42	  
	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  1154	   169	   3.77	   4.02	   3.97	   3.97	   3.96	   3.95	   3.96	   4.01	   3.97	   3.92	   3.97	   3.94	   3.97	   3.97b	   -­‐0.20	  
1156	   60	   4.22	   4.54	   4.24	   4.42	   3.99	   4.47	   4.48	   4.45	   4.30	   4.48	   4.45	   4.43	   4.45	   4.39b	   -­‐0.17	  
1161	   36	   4.43	   3.33	   2.01	   2.24	   2.04	   2.43	   2.38	   2.34	   2.27	   2.42	   2.38	   2.36	   2.43	   2.38b	   2.05	  
1186	   14	   4.84	   3.36	   3.46	   3.47	   3.02	   3.49	   3.47	   3.49	   3.38	   3.53	   3.48	   3.51	   3.46	   3.43b	   1.42	  
1247	   31	   4.51	   4.80	   4.83	   4.84	   4.71	   4.88	   4.89	   4.84	   4.78	   4.94	   4.86	   4.85	   4.92	   4.84b	   -­‐0.34	  
1248	   54	   4.84	   4.69	   4.75	   4.74	   4.65	   4.78	   4.79	   4.77	   4.68	   4.84	   4.76	   4.74	   4.82	   4.75b	   0.09	  
1439	   158	   3.80	   4.40	   4.38	   4.41	   4.37	   4.39	   4.41	   4.44	   4.41	   4.41	   4.34	   4.34	   4.39	   4.39b	   -­‐0.59	  
1455	   163	   3.79	   4.27	   4.32	   4.33	   4.32	   4.32	   4.30	   4.33	   4.34	   4.31	   4.31	   4.29	   4.34	   4.31b	   -­‐0.53	  
1458	   >3000	   2.52	   3.06	   3.64	   3.44	   3.33	   3.38	   3.39	   3.36	   3.44	   3.39	   3.45	   3.47	   3.45	   3.40b	   -­‐0.88	  
1466	   72	   4.14	   4.40	   4.41	   4.46	   4.39	   4.45	   4.45	   4.51	   4.47	   4.45	   4.38	   4.39	   4.46	   4.43b	   -­‐0.30	  
1467	   22	   4.65	   3.54	   3.74	   3.81	   3.44	   3.79	   3.80	   3.83	   3.80	   3.83	   3.79	   3.81	   3.82	   3.75b	   0.90	  
1483	   190	   3.72	   4.23	   4.37	   4.34	   4.34	   4.25	   4.34	   4.34	   4.37	   4.34	   4.36	   4.33	   4.35	   4.33b	   -­‐0.61	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Table 3.3 Related statistics and field contribution of CoMSIA results. 
	   	   	  
test	  sets	  
	   	   	  
training	  set	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	  
q2	  a	   0.73	   0.714	   0.746	   0.779	   0.730	   0.734	   0.719	   0.699	   0.721	   0.709	   0.703	   0.736	  
R2	  b	   0.991	   0.966	   0.991	   0.989	   0.991	   0.992	   0.994	   0.982	   0.991	   0.994	   0.991	   0.992	  
F	  test	  c	   410	   156	   386	   304	   383	   389	   511	   232	   385	   514	   360	   401	  
N	  d	   6	   4	   6	   6	   6	   6	   6	   5	   6	   6	   6	   6	  
N	  e	   29	   27	   27	   27	   27	   27	   27	   27	   27	   27	   27	   27	  
	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  %	  steric	   5	   4.4	   4.9	   3.7	   4.9	   5.2	   5	   4.9	   4.9	   5.1	   5.2	   5.1	  
%	  electrostatic	   37.2	   35.3	   37	   34.5	   37.7	   38.2	   37.8	   35.6	   37.5	   37.1	   27.3	   37.6	  
%	  hydrophobic	   16	   16.7	   15.3	   16.7	   15.9	   15.6	   15.6	   15.8	   15.2	   15.9	   15.5	   16.3	  
%	  donor	   21.4	   23.6	   22.4	   24.5	   20.2	   21	   21.4	   24.2	   21.6	   21.2	   21.6	   19.4	  
%	  acceptor	   20.4	   20.1	   20.5	   20.7	   21.3	   20	   20.2	   19.4	   20.6	   20.7	   20.4	   21.6	  
a Cross-validated R2. B Correlation coefficient. c Ratio of R2 explained to unexplained = R2/(1-R2). 
d Optimal number of principle components. e Number of compounds. 
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Chapter 4: Chemo-Immunotherapeutic Anti-Malarials Targeting 
Isoprenoid Biosynthesis 
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4.2	  Introduction	  
Malaria is a major cause of mortality and morbidity from parasitic protozoan diseases 
worldwide [1] and there is now resistance to the newest drug, artemisinin (18, Scheme 1.6) [2]. 
There is thus interest in new drugs and new drug targets, as well as unconventional approaches 
involving host innate immunity [3,4]. Activated γδ T cells are of interest in this context since not 
only can they kill tumor cells [5], bacteria [6] as well as influenza virus-infected cells [7], but 
they have also recently been found to kill the invasive, extracellular (merozoite) form of the 
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malaria parasite, Plasmodium falciparum [3]. In addition, γδ T cells produce TNF-α on 
activation, and TNF-α is known to prevent the development of pre-erythrocytic stage parasites 
[8]. One class of drug molecules called bisphosphonates are known to activate γδ T cells 
(containing the Vγ2Vδ2 T cell receptor), so these molecules might be used as 
immunomodulators, activating γδ T cells [9]. Most bisphosphonates are, however, poorly taken 
up into cells and bind tightly to bone mineral [10], but in recent work we showed that ‘lipophilic’ 
bisphosphonates [11] were more active in γδ T cell activation [12] than were the current 
bisphosphonate drugs, used to treat bone resorption diseases and cancer. We also discovered that 
lipophilic bisphosphonates were active in killing liver stage malaria parasites [13], and that a 
lipophilic analog of the bisphosphate zoledronate was a potent inhibitor of the intra-erythrocytic, 
red blood cell form of Plasmodium falciparum that was also active in vivo, in mice [14]. These 
results prompted us to see whether we could make analogs of zoledronate that would kill malaria 
parasites directly, as well as activate human γδ T cells.  
 Bisphosphonates such as zoledronate (1) activate γδ T cells by inhibiting the enzyme 
farnesyl diphosphate synthase (FPPS) which results in accumulation of the FPPS substrates, 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), both of which are 
“ phosphoantigens” that activate γδ T cells [12,15]. However, zoledronate has essentially no 
effect on the intra-erythrocytic form of the malaria parasites since it is poorly membrane 
permeable. In contrast, lipophilic bisphosphonates (containing N-alkyl side-chains) do kill the 
parasites [14]. Here, the target is the Plasmodium geranylgeranyl diphosphate synthase (GGPPS). 
This enzyme is unusual in that is structrually more similar to human FPPS than huamn GGPPS 
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and – unlike human GGPPS, is potently inhibited by bisphosphonates. Inhibiting GGPPS in the 
parasite blocks formation of protein prenylation [16] as well as carotenoid [17], menaquinone 
[18] and vitamin E formation [19], Figure 4.1, and results in “direct” parasite killing. 
Here, we sought to determine if we could find a lipophilic bisphosponate that would both 
kill malaria parasites directly (by inhibiting GGPPS) as well as indirectly, by activating γδ T 
cells. 
4.3	  Results	  and	  Discussions	  
We synthesized the 16 pairs of zoledronate species (1-32) shown in Figure 4.2a in which we 
varied the length of the alkyl chain (n=0 through n=15 carbons) and the presence or absence of 
the 1-OH group that is involved in bone-binding and that has been proposed with zoledronate to 
be important in γδ T cell activation [10,20]. Synthesis and characterization details are in the 
Supporting Information. We then tested all 32 compounds for FPPS inhibition activity. The most 
potent FPPS inhibitors were those with medium length side-chains and these were ~3-10x more 
potent than zoledronate itself, Figure 4.2b and Table 4.1. As the N-alkyl chain length increases 
beyond C10, FPPS inhibition decreases, due presumably to the onset of steric repulsion with the 
highly conserved Phe-98,99 residues in the FPPS active site that limit chain elongation.  
 We next investigated the effects of chain-length and the presence/absence of the 1-OH 
group on γδ T cell activation, as determined in a TNF-α release assay [21]. As can be seen in 
Table 4.1 and Figure 4.2c, there is a monotonic increase in activity with both series of 
compounds with increasing chain length up to n~11, then activity decreases with n>12. The 
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decrease in activity with the longer chain species occurs at a longer chain length in cells than in 
FPPS inhibition, due we believe to the importance of hydrophobicity (with the more lipophilic 
species), which facilitates cell entry. These results also clearly show–at least with the cell lines 
we have used - that there is no major difference in activity in cells due to the presence or absence 
of the 1-OH group.  
To see how these lipophilic zoledronate derivatives bound to FPPS, we obtained the x-ray 
crystallographic structure of 5 (IC50 ~ 30 nM) bound to HsFPPS, as shown in Figure 4.3a (in 
cyan; PDB ID code 4GA3). Full crystallographic data acquisition and structure refinement 
details are given in Supporting Information Table 4.2. 
The electron density map is shown in Figure 4.3b. 5 binds into the same site as does 
zoledronate [22,23] with its two phosphonate groups bound to the [Mg2+]3 cluster, and there is a 
0.7 Å rmsd between the [Mg2+]3, bisphosphonate and imidazole rings in the two structures. The 
alkyl chain extends into the GPP/FPP side-chain site, Figure 4.3c (FPPS structures, PDB ID code 
1UBX and 1UBW). The origin of the more potent FPPS inhibition by the N-alkyl 
bisphosphonates over that seen with the unsubstituted species is likely due to an enhanced 
hydrophobic interaction as opposed to a purely Coulombic interaction, since the results of a 
solid-state NMR and quantum chemical investigation [24] show that the imidazole nitrogen in 
zoledronate also carries a +1 charge (due there to protonation), when bound to FPPS. 
We next investigated the inhibition of Plasmodium vivax GGPPS by 1-32, as well as the 
direct killing of intra-erythrocytic parasites by these compounds. As can be seen in Figure 4.2d, e 
and Table 1, several of the compounds most effective in inhibiting PvGGPPS were also very 
128 
 
effective in inhibiting P. falciparum growth (Figure 4.4a, green circle). The correlation between 
PvGGPPS and cell growth inhibition was poor (Figure 4.4.a, R= 0.08) but improved to R= 0.84 
(Figure 4.4b) on addition of the logP (octanol/water partition coefficient) and E_sol (solvation 
energy) descriptors reported previously [25]. The ability to inhibit FPPS as well as GGPPS with 
the same chain length compounds is likely due to their mimicking the FPP product (in human 
FPPS) or the FPP substrate (in Plasmodium GGPPS), together with the presence of the “third 
Asp” in PvGGPPS that is essential for bisphosphonate binding to [Mg2+]3 with, and as can be 
seen in Figure 4.3d, the structures of 5 bound to HsFPPS and 29 bound to PvGGPPS are very 
similar (rmsd=0.9 Å). 
4.4	  Conclusions	  
The results we have presented here are of interest for a number of reasons. First, we 
constructed a library of 32 N-alkyl analogs of the bisphosphonate drug, zoledronate, with and 
without 1-OH groups, and tested them for activity in inhibiting human FPPS. The results show 
that medium chain length species inhibit human FPPS most potently, while longer chain species 
are inactive, due we propose to a steric clash with the FPPS chain-length-determining residues 
F98, 99. Second, we investigated the activity of all 32 compounds in γδ T cell activation: the 
most active species had 10±1 carbons in the N-alkyl side-chain. We propose that the increased 
activity of these lipophilic zoledronate-analog bisphosphonates in cells compared with 
zoledronate itself is due to the improved cell uptake of the more lipophilic compounds. Third, we 
determined the x-ray crystallographic structure of one potent inhibitor of human FPPS bound to 
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the enzyme, finding that the bisphosphonate and imidazole groups occupied the same position as 
in zoledronate bound to FPPS, as well as 29 bound to GGPPS. Fourth, we find that the most 
potent Vγ2Vδ2 T cell activators also kill malaria parasites in vitro (and in vivo [14]). This opens 
up the intriguing possibility of a combined chemo-immunotherapeutic approach to the 
development of new anti-malarials in which both host host innate immunity (host FPPS 
inhibition/γδ T cell activation/ TNF-α and granulysin-mediated killing of liver stages and 
merozoites) as well as direct killing (parasite GGPPS inhibition/prenylation, carotenoid, 
menaquinone and vitamin E biosynthesis) are targeted by a single molecule. 
4.5	  Materials	  and	  Methods	  
4.5.1	  Human	  FPPS	  Expression	  and	  Inhibition	   	  
Truncated human FPPS (6~353) was cloned into NdeI/BamHI restriction sites of pET28a vector 
by using forward primer 
(5’-CTTCATATGAATTCAGATGTTTATGCCCAAGAAAAGCAGGATTTCG-3’) and 
reverse primer (5’-CTTGGATCCTCACTTTCTCCGCTTGTAGATTTTGCGCG-3’). 
pET28a-(His)6HsFPPS_6~353 was transformed into BL21(DE3) Tuner cells to ensure proper 
distribution of inducers across the cells. Transformed cells were spread onto LB plates with 50 
µg/mL kanamycin and were incubated for 16 hours. A single colony that carried 
pET28a-(His)6HsFPPS_6~353 was inoculated in 100 mL LB broth with 50 µg/mL kanamycin 
and was incubated at 37 °C overnight. 10 mL of inoculated cells were added into 1L LB broth 
with 50 µg/mL kanamycin and was incubated until the OD600 reached 0.6~0.8. Cells were 
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induced by 1mM IPTG and incubated at 24°C for at least 16 hours then centrifuged and the 
pellets frozen at -80 °C. Next, the cell pellets were thawed in wash buffer (10 mM HEPES, pH 
7.5, 500 mM NaCl and 35 mM imidazole) with addition of Benzonase (EMD Millipore) and 
EDTA-free protease cocktail (Roche). Thawed cells were sonicated (10sec active, 20sec rest, for 
10min) then centrifuged at 23,000 rpm for 30 min. The supernatant was loaded on Ni-NTA 
column and eluted with 0~100% elution buffer (10 mM HEPES, 500 mM NaCl and 500 mM 
imidazole). Fractions were subjected to SDS-PAGE and only pure (His)6HsFPPS was collected. 
The protein was digested with thrombin and dialyzed against dialysis buffer (10 mM HEPES, pH 
7.4 and 150 mM NaCl) at 4 °C for 30 hours to remove the N-terminal His-tag. HsFPPS was 
further purified by using S200 gel filtration chromatography with storage buffer (10 mM Tris, 
pH 7.4 and 25 mM NaCl). The pure HsFPPS fraction was concentrated to 37 mg/mL, then 
quickly frozen under liquid nitrogen and stored at -80°C. 
Human FPPS inhibition assays were carried out using 96 well plates with 200 µL 
reaction mixture in each well. The condensation of geranyl diphosphate and isopentenyl 
diphosphate was monitored at room temperature by a continuous spectrophotometric assay for 
phosphate-releasing enzymes. The reaction buffer contained 50 mM Tris-HCl (pH 7.4), 1 mM 
MgCl2, and 0.01 % Triton X100. The compounds investigated were pre-incubated with enzyme 
for 30 min at room temperature. The IC50 values were obtained from fitting dose-response curve 
using Prism 4.0 [26]. 
4.5.2	  P.	  vivax	  GGPPS	  Expression	  and	  Inhibition	  
(Note: Inhibition assay was done by Wei Zhu.)  
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A clone encoding P. vivax GGPPS (PlasmoDB gene ID: Pv092040) with an N-terminally 
His6-tagged fusion protein and a tobacco etch virus protease site was expressed in Escherichia 
coli BL21-codon Plus (DE3) RIL (Stratagene) at 15 °C in baffled flasks. Cells were lysed by 
sonication in the presenceof Benzonase Nuclease (Novagen) and a protease inhibitor cocktail 
(Sigma), and the protein was then purified chromatographically by using a Ni-nitrilo-triacetate 
resin. EDTA was added immediately to the elution fraction to 1 mM and 5 mM DTT added after 
15 min. The eluted protein was then concentrated and loaded onto a Sephadex S-200 gel 
filtration column, and fractions containing PvGGPPS collected. The P. vivax GGPPS inhibition 
assays were carried out by using 96-well plates with 200 µL of reaction mixture in each well. 
The condensation of geranyl diphosphate (GPP) with isopentenyl diphosphate (IPP) was 
monitored at room temperature by using a continuous spectrophotometric assay for 
phosphate-releasing enzymes in a reaction mixture containing 50 mM Tris-HCl (pH 7.4), 1 mM 
MgCl2, and 0.01% Triton X100. The inhibitors were pre-incubated with the enzyme for 30 min, 
at room temperature. The IC50 values were obtained from fitting the dose-response curve using 
Prism 4.0 (GraphPad Software, Inc., La Jolla, CA, www.graphpad.com). 
4.5.3	  γδ	  T	  cell	  Activation	  Assays  
(Note: This part was done by Dr. Morita’s group.) 
Vγ2Vδ2T cell activation was assessed by TNF-α release as described previously.[27] 
Briefly, the CD4+ Vγ2Vδ2T cell clone, JN.23, was stimulated with bisphosphonates in the 
presence of the antigen presenting cell line, CP.EBV (an EBV transformed human B cell line). 
For TNF-α release, supernatants were harvested 16 h later and assayed for TNF-α levels by 
132 
 
sandwich ELISA (R&D Systems). Concentrations required to achieve 50% of the observed 
maximal T cell response (EC50) were obtained by using the Prism 4.0 program (Graphpad 
Software, La Jolla, CA, www.graphpad.com), using a sigmoidal dose-response function. Curve 
fitting minima for each experiment were determined using the Global Fitting technique, as 
implemented in Prism 4.0. Curve fitting maxima were optimized for each individual compound 
without the use of any constraints.  
4.5.4	  Crystallization,	  Data	  Collection	  and	  Refinement	  of	  the	  HsFPPS•5	  Complex	  
Co-crystallization of human FPPS was set up under the following conditions. 34 mg/mL 
HsFPPS was mixed with 1 mM compound 5 and 2 mM MgCl2. The mixture was then incubated 
at 4 °C overnight. The mixture was centrifuged and any precipitate discarded. The protein 
solution was mixed with 1.2 M Na/K phosphate (pH 5.2) and 25% glycerol by hanging drops in 
a ratio of 1:1. Crystallization drops were incubated at 18 °C. Large, hexagon-like crystals 
appeared in ~ 1-3 days and grew to maximum size in one week. The crystals were mounted, and 
then frozen in liquid nitrogen. Diffraction data was collected at Life Science Collaborative 
Access Team (LS-CAT) in Argonne National Laboratory (Argonne, IL). Data was processed by 
using HKL2000 [28] and refined by using CCP4 [29] and COOT [30]. Refined statistics are 
shown in Table 4.2. Graphics were created by using PyMOL [31]. 
4.5.5	  P.	  falciparum	  Growth	  Inhibition	  Assays	   	  
(Note: This part of work was done by Dr. Joo Hwan No and Lucio H. Freitas-Junior’s group at 
Institut Pasteur Korea.) 
P. falciparum growth inhibition assays were carried out as described in our previous 
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work[14].  P. falciparum culture was adjusted to 2% hematocrit, 0.5% parasitemia, dispensed 
by a WellMate (Thermo) to 384 well plates (Greiner) containing the compounds (final volume 
50 µL) and incubated for 72 h. Chloroquine, artemisinin, and DMSO were used within the assay 
plates to serve as controls. After 3 d, a parasite lactate dehydrogenase (pLDH) assay was used to 
assess drug efficacy. At the end of 72 h, the plates were frozen overnight at −20 °C. After 
thawing, the plates were shaken for 45 s at 1,700 rpm in a Mix Mate (Eppendorf) and 5 µL of the 
lysate transferred into the corresponding well of another plate containing 30 µL of Malstat 
Reagent [32] and incubated for 2 h. The absorbance (650 nm) was read using a Spectramax M5 
(Molecular Devices). IC50 values were obtained from fitting the dose-response curve using Prism 
4.0 [26]. 
4.5.6	  Computational	  Aspects	  
(Note: This part was done by Wei Zhu.) 
We performed a complete combinatorial descriptor search in MATLAB [33], using linear 
regression of enzyme pIC
50
 plus all possible two-descriptor combinations (
150
C
2
 = 11  175 
combinations for a database containing 150 descriptors, for example, against the cell activities, 
pIC
50
(cell). For the leave-two-out (L2O) cross-validation, the same exhaustive search was 
performed, using a training set obtained by leaving out two compounds from the initial data set. 
This process was repeated for all pairwise combinations of the compounds. So, if there are 32 
compounds (as in P. vivax), then each compound is left out (and predicted) 31 times. In this way, 
for P. vivax GGPPS we obtained 31 predicted values for each compound in the data set, and 
these were then averaged to give the overall leave-two-out predicted value, for each compound. 
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To test whether the correlations obtained might occur by chance, we randomly scrambled the cell 
activities, then performed the leave-two-out validation on the scrambled data. The process was 
repeated 10 times, and the mean R
2
 values are reported. For the 10 systems investigated, each 
scrambling analysis requires 10−90 h, depending upon the number of descriptors (80−150) 
and the number of compounds (21−102) in the data set. Linearly dependent descriptors were 
eliminated based on the occurrence of rank deficiency in the descriptor correlation matrix (in 
MATLAB [33]). Note: from the previous our publication [34], we knew the optimal descriptors 
for Plasmodium cell and enzyme activities are logP and solvation energy. Thus, we directly 
applied these descriptors in our current data without the initial descriptors search.  
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4.6	  Figures	  and	  Tables	   	  
Figure 4.1 Schematic illustration of pathways involved in zoledronate analogs activity in γδ T 
cells to kill extracellular parasites and in Plasmodium to kill intracelluar parasites. Green = 
human cell; cyan = malaria parasite. HMG-CoA = hydroxymethylglutaryl coenzyme A; IPP = 
isopentenyl diphosphate; DMAPP = dimethylallyl diphosphate; FPP = farnseyl diphosphate; 
GAP = glyceraldehyl-3-phosphate; HMBPP = 4-hydroxyl-3-methyl-but-2-enyl diphosphate; 
GGPP = geranylgeranyl diphosphate; TNF-α = tumor necrosis factor α; INF-γ = interferon-γ. 
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Figure 4.2 Chain length dependence of enzyme and cell growth inhibition and effects of the 
1-OH group. (a) Structures of compounds investigated. (b) HsFPPS. (c) γδ T cell activation/ 
TNF-α release; (d) PvGGPPS inhibition; (e) Intra-erythrocytic P. falciparum cell growth 
inhibition. 
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Figure 4.3 Structural results. (a) X-ray structure of HsPPPS•5 complex (cyan, PDB ID code 
4GA3) superimposed on PvGGPPS structure (purple, PDB ID code 3RBM). The Cα rmsd over 
331 residues in 1.44 Å. (b) Electron density map of 5 bound to HsFPPS.  (c) Comparison 
between the x-ray structures of 5 bound to HsFPPS, GPP (yellow) and FPP (green) bound to 
avian FPPS (PDB ID code, 1UBW, 1UBX). The bisphosphonate 5 bound to the allylic (GPP, 
FPP) site with its side-chain located in the GPP/FPP sidechain site. Chain elogation in FPP is 
blocked by F98, F99, corresponding to decreased HsFPPS inhibition by bisphosphonate 
inhibitors with N-alkyl chains longer than ∼C10. (d) Structures of HsPPPS•5 overlaid on 29 
(BPH-703) bound to PvGGPPS (PDB ID code 3RBM). The bisphosphonate, imidazolium and 
N-alkyl side-chain structures are quite similar. Optimum activity in PvGGPPS is at ∼C11, then 
steric repulsion occurs. 
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Figure 4.4 In corporation of descriptors search on Plasmodium cell activities and enzyme 
activities. (a) Original data show the correlation between pIC50 (Plasmodium cell activities) and 
pIC50 (PvGGPPS enzyme activities) in a total of 32 compounds. Green circle indicates those 
compounds with good cell and enzymes inhibitions. (b) Data of (a) after in corporation of two 
descriptors (logP(o/w) and E-sol (solvation energy)). pIC50(Plasmodium) = a•pIC50(PvGGPPS) + 
b•logP(o/w) + c•E_sol + d. (Courtesy of Wei Zhu) 
  
139 
 
Table 4.1 Enzyme inhibition together with γδ T cell activation and P. falciparum cell growth 
inhibition. 
 
Sidechain HsFPPS TNF-α PvFPPS P. falciparum 
 
Length IC50 IC50 IC50 IC50 
ID (n, OH/H) (µM) (µM) (µM) (µM) 
1 0, OH 0.10 170 0.13 >300 
2 1, OH 0.080 210 0.15 >300 
3 2, OH 0.049 160 0.12 >300 
4 3, OH 0.034 190 0.16 >300 
5 4, OH 0.030 250 0.14 >300 
6 5, OH 0.049 170 0.12 97 
7 6, OH 0.044 81 0.12 25 
8 7, OH 0.040 47 0.055 14 
9 8, OH 0.036 23 0.039 7.1 
10 9, OH 0.080 23 0.047 11 
11 10, OH 0.23 4.9 0.082 14 
12 11, OH 1.5 4.1 0.33 17 
13 12, OH ND ND ND ND 
14 13, OH 8.3 110 2.7 44 
15 14, OH 42 160 3.2 >300 
16 15, OH 60 280 7.1 >300 
17 0, H 0.14 140 0.16 >300 
18 1, H 0.19 210 0.16 >300 
19 2, H 0.08 180 0.17 >300 
20 3, H 0.066 200 0.14 100 
21 4, H 0.079 280 0.13 51 
22 5, H 0.11 160 0.20 22 
23 6, H 0.058 56 0.21 8.6 
24 7, H 0.044 36 0.15 7.2 
25 8, H 0.040 17 0.13 4.1 
26 9, H 0.043 12 0.13 3.3 
27 10, H 0.10 15 0.14 1.3 
28 11, H 0.28 10 0.14 2.5 
29 12, H 0.37 13 0.31 2.7 
30 13, H 0.35 51 0.38 8.8 
31 14, H 3.0 94 1.1 120 
32 15, H 8.3 210 4.5 150 
 
  
140 
 
Table 4.2 Data collection and refinement statistics. Values in parentheses correspond to the 
highest resolution shell. 
Crystal HsFPPS-5 
PDB ID 4GA3 
Data collection 
Radiation source LS-CAT 21-ID-G 
Wavelength (Å) 0.97857 
Space group P41212 
a (Å) 112.29 
b (Å) 112.29 
c (Å) 68.55 
Resolution (Å) 50.0-2.40 
 
(2.44-2.40) 
No. of reflections 17314 (882) 
Completeness (%) 97.4 (99.7) 
Redundancy 16.1 (16.4) 
Rmerge (%) 8.3 (63.5) 
I/σ(I) 53.9 (7.52) 
Refinement 
Resolution (Å) 40.5-2.40 
(2.44-2.40) 
No. of reflections 16394 (987) 
Rwork (%) 20.4 (26.0) 
Rfree (%) 28.2 (35.1) 
Geometry deviations 
Bond lengths (Å) 0.016 
Bond angles (°) 1.937 
Mean B-values (Å2) / number of non-H 
atoms All refined atoms 43.5/2909 
Compound atoms 30.2/20 
PO4 ions 54.4/10 
Mg ions 20.4/3 
Water molecules 39.0/70 
Ramachandran plot (%) 
Most favored 93.9 
Additionally allowed 6.1 
Generously allowed 0 
Disallowed 0 
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